ビジネスワイヤ(バフェットのBerkshire Hathaway group)

【朗報】WinX DVD Ripper Platinum無料!日本独自コピーガード… 2017年03月25日 08時00分

CHENGDU, China--(BUSINESS WIRE)--(ビジネスワイヤ)--メディアソフトウェア開発会社Digiarty
Software, Inc
は日本の定番DVDコピーソフトWinX DVD Ripper PlatinumとMac版のMacX DVD
Ripper Proを再開発して、3月22日に最新バージョンWinX
DVD Ripper Platinum 8.5.0
とそのMacX DVD Ripper Pro
5.5.0をリリースしました。DVD変換/コピーの体験の最も大切な部分を劇的に進化させました。先進的な新しいハードウェアアクセラレーション技術。日本独自のコピーガードに対応したDVD
Disc File System。これまでのバージョンの中で最高の解除力と圧倒的な速さ。最も安定、最も使いやすい、最も高品質。DVD
ShrinkやDVD
Decrypterでコピーできない日本独自のDVD及びダイエットDVDをサポートし、市場のすべてのDVDファイルシステムとコピーガードに対応する唯一のソフトになりました。新しいハードウェアアクセラレーション技術を搭載し、業界一の爆速でDVDをリッピングします。




【WinX DVD Ripper Platinum最新バージョン詳細】




お客様が最新のDVDがコピーできるように、Digiarty社は今期間限定でWinX DVD Ripper PlatinumとMacX DVD
Ripper Proの最新バージョンを無料配布するTwitter懸賞キャンペーンを開催しております。まずWinX DVD Ripper
PlatinumとMacX DVD Ripper Pro新バージョンの特徴をご覧下さい。



★ 注目の新機能--日本独自DVDコピーガードに唯一対応



日本制の一部のDVDのみに施されたコピーガードに対応しているのはWinX DVD Ripper PlatinumとそのMac版MacX DVD
Ripper Proだけです。DVDファイルシステムISO
9660をサポートし、一部DVDはVLCなどのメディアプレーヤーで再生できない、DVDフォルダにあるはずのVOB, IFO,
BUPファイルがない場合、WinX DVD Ripper PlatinumでDVDをMP4に変換すれば問題なく再生できます。その上、DVD
Shrink、DVD Decrypterなどの定番ソフトでエラー頻発DVD、99タイトルのDisney
X-project DRM
や容量偽装などのコピーガードに対応するテクニックを改めて開発され、より速く且つ正確に複数のダミー映像タイトルから正しいタイトルを自動的に検出することができました。



★ Intel QSVとNVIDIA (CUDA)NVENCの技術により、DVD変換速度を5倍速まであげる!業界No.1!



IntelのQuick Sync
Video(QSV)アクセラレーションを利用したH.264エンコードやNVIDIAが提供する「NVENC」によるH.264エンコードなど、CPU
と GPU のハードウェアアクセラレーションのサポートを追加しました。(MacX DVD Ripper
ProはVideoToolboxハードウェアアクセラレーション技術)これによって、X32のDVDドライブでテストしたところでは、WinX DVD
Ripper Platinumは、DVDをMP4(H.264)に変換するスピードがハードウェアアクセラレーション技術を利用しない時の5倍の500
fpsになります。5分間で一枚の市販DVDをコピー可能になります。またCPUの使用率も大幅に減ります。



弊社は日本でよく使われるWindows用DVDコピーソフトのISOイメージへの変換速度をテストしました。結果は以下のようになっています。



※ 動作環境:Windows 10 Pro 64bit, Intel(R) Core(TM) i5-4460 CPU @
3.20GHz(3201 MHz), 8.00 GB (1600 MHz)



※ DVD情報:A touch of f**、時間:01:33:34、サイズ:4.1GB












































































































































































 

 

 

WinX DVD Ripper Platinum

 

 

Handb**

 

 

AnyD**

 

 

CloneM**

 

 

DVD Decrypter

 

 

DVD Shrink

コピーガード

 

 



 

 



 

 



 

 



 

 



 

 



ハードウェアアクセラレーション

 

 



 

 



 

 



 

 



 

 



 

 



DVD読み込む時間

 

 

3s

 

 

12s

 

 

16s

 

 

18s

 

 

21s

 

 

24s

CPU使用率

 

 

1%

 

 

2%

 

 

5%

 

 

7%

 

 

12%

 

 

11%

時間

 

 

6.5min

 

 

21min

 

 

18.5min

 

 

24.8min

 

 

29.4min

 

 

22min

Avg FPS

 

 

340fps

 

 

294fps

 

 

260fps

 

 

237fps

 

 

189fps

 

 

121fps


 

 


 

 


 

 


 

 


 

 


 

 



早速新しい体験へ



Win版:https://www.winxdvd.com/dvd-ripper-platinum/index-jp.htm



Mac版:http://www.macxdvd.com/mac-dvd-ripper-pro/index-jp.htm



WinX DVD Ripper Platinum無料ゲット!(Mac版も)



これまでのバージョンの中で最高の解除力と最速い変換スピードを体験したい方へ、Digiarty社は期間限定でWinX DVD Ripper
PlatinumとMacX DVD Ripper Proのライセンスコードを無料で提供するTwitter懸賞キャンペーンを開催しております。



WinX DVD Ripper Platinum無料入手方法



弊社の公式Twitterアカウント@DigiartyIncをフォローして、@DigiartyIncが固定されたツイートを欲しがる製品名付いて返信及びリツイートして、弊社が先着順の200名様に欲しがる製品のライセンスコードをダイレクトメッセージで送信いたします。



会社情報



Digiarty Software, Inc.はWindows、Mac OS XもしくはiOS 9、Apple iPhone、iPad、Sony
PS4、
PSP、Surface、Xbox、Androidといったプラットフォームやデバイスから、家庭個人用のビデオオーディオソフトウェアまで様々なツール等を開発しているマルチメディアソフトウェアのスペシャリスト集団です。またDVDコピー、DVD変換、HD動画変換、DVD作成等に対応したソフト開発、サービスも提供しております。製品群は、現在に至るまで世界中の個人のみならず、法人、政府機関、学術機関でご活用いただいております。Digiarty
Software社の製品を一度購入したら、一生涯に無料で最新バージョンをアップグレードことができます。




Contacts


Digiarty Software Inc.
Han Zhicai, +86-28-85134884
business@winxdvd.com
ホームページ:http://www.winxdvd.com/index-jp.htm(for
Windows user)
ホームページ:http://www.macxdvd.com/index-jp.htm(for
Mac user)

GA-ASI、「ジャパン・ドローン」で日本との協力を発表 2017年03月25日 00時51分

サンディエゴ & 東京--(BUSINESS WIRE)--(ビジネスワイヤ) --
遠隔操縦航空機(RPA)システム、レーダー、電子光学および関連ミッションのシステムソリューションの大手メーカーであるジェネラル・アトミクス・エアロノーティカル・システムズ(GA-ASI)は本日、千葉県の幕張メッセで開催中のジャパン・ドローン展示会で行った記者会見の中で、日本の民間非隔離空域における中高度長時間滞空(MALE)RPAの運航承認の加速を目指し、日本の産業界、政府、学術界のグループから成るコンソーシアムとの間で研究協力契約を締結したと発表しました。




GA-ASI航空機システム・プレジデントのデビッド・R・アレキサンダーは、次のように述べています。「今回の提携から得られる航空管制、通信技術、運航に関する専門知識により、当社のガーディアン航空機とその他のRPAのために日本の空域統合コンセプトを検証する当社の取り組みが促進されます。現地での提携と日本の民間空域でのRPAの容認達成に向けたその貢献は、これらのコンセプトの検証における最初の主要なステップです。」



今回の提携は、日本で最初の民間MALE
RPA飛行の承認確立と、公共・民間運航に向けたそのユーティリティーの検討を目指すものです。海に囲まれ、地震、津波、台風などの自然災害の被害を頻繁に受けている日本は、被害に負けない状況認識能力と通信能力を大いに必要としています。ガーディアンなどのRPAは、これらのニーズの満足に重要な役割を果たすと期待されています。



GA-ASIのオオツボ・ノブユキ戦略開発担当ディレクターは、次のように述べています。「災害救援や国境警備などの人道的活動に貢献して日本の社会的優先課題を支えることを目指し、RPAのミッション遂行能力を最大限に引き出す枠組みを探ることが重要と考えます。」



GA-ASIがジャパン・ドローンで行った記者会見では、日本周辺地域の監視の大きな必要性が強調されました。例えば、海上保安庁は日本の陸地面積の12倍に相当する地域を監視しています。この地域は、排他的経済水域、捜索・救助、緊急災害救援の対象地域です。ガーディアンは、そうした監視活動を行って今日の日本にとって重要な情報を提供するよう特別に設計された航空機です。これは、複数領域の課題に向けた複数機関のソリューションを代表しています。GA-ASIは、今年中にその技術のデモを行えるよう、日本のいくつかの機関と取り組んでいきます。



今回の提携の長期目標は、日本の非隔離空域でGA-ASIが設計したガーディアンを飛行させ、RPAのミッション遂行能力を拡大することです。現在、日本にはRPAの空域規制はなく、今回の新たな提携はそれに関する先駆的なプログラムとなるよう努めます。



GA-ASIについて



ジェネラル・アトミクス傘下のジェネラル・アトミクス・エアロノーティカル・システムズは、世界中の軍事・民間アプリケーション向けに遠隔操縦航空機システム、レーダー、電子光学および関連ミッションのシステムソリューションを通じて、状況認識能力を提供しています。当社の航空機システム事業部門は、プレデター®A、プレデターB/MQ-9リーパー®およびプレデターB/MQ-9リーパー・エクステンデッド・レンジ(ER)、グレイ・イーグルおよびグレイ・イーグルER、プレデターCアベンジャー®およびアベンジャーER、プレデターXP、スカイガーディアンTMおよびシーガーディアンTMなど、実績ある信頼性に優れたRPAシステムの設計と製造でリードしています。また、次世代のアドバンスド・コックピットGCSを含む、さまざまなソリッドステートデジタルGCSを製造して、パイロットのトレーニングとRPAフィールド運用のためのサポートサービスも提供しています。ミッション・システムズ事業部門は、リンクス・マルチモード・レーダーと、高度なクロー・センサー制御および画像分析ソフトウエアの設計・製造に加え、有人航空機と遠隔操縦航空機の両方にそれらの組み込みを行っています。また同部門は、情報・監視・偵察(ISR)航空機プラットフォーム向けの統合型センサー・ペイロードやソフトウエアの提供にも注力し、高エネルギー・レーザー、電子光学センサー、メタマテリアル・アンテナの開発も手掛けています。詳細情報については、www.ga-asi.com.をご覧ください。



Reaper、Predator、Avenger、Lynx、およびClawはジェネラル・アトミクス・エアロノーティカル・システムズの登録商標です。SkyGuardianおよびSeaGuardianはジェネラル・アトミクス・エアロノーティカル・システムズの商標です。



本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。




Contacts


General Atomics Aeronautical Systems, Inc.
Melissa Haynes, +1 (858)
524-8108
asi-mediarelations@ga-asi.com

Specialist Knifemaker Kamikoto Enjoys Resurgence with Handm… 2017年03月24日 21時00分

TOKYO--(BUSINESS WIRE)--Kamikoto, the original manufacturer of Japanese Niigata steel knives, is
building a growing reputation for their handmade Niigata steel knives in
the US.








Japan’s reputation for blades dates back to the 13th century, and these
traditions have directly translated to how the Kamikoto master knife
crafters make knives to this day. This dedication appears to have paid
off, with the brand finding double digit growth and recognition amongst
a growing audience in the West.



Kamikoto’s expertise is apparent from the weight and selection of steel
to the finish. The best-selling Kanpeki Knife Set features a meat
cleaver, a slicing knife and a utility knife in superb Niigata steel.
“Kamikoto knives may be made by experts, but even home cooks can benefit
from having a good knife in the kitchen. And not just sushi, these are a
good set of knives for almost any cuisine. We want our clients to use
these knives every day, and to feel our honest approach, and authentic
design. Our success gives us hope. It’s a huge impetus to our craft.
This allows us to tell the stories through our traditional design and to
reach a global audience for years and years to come.”



Like other brands focused on craft, Kamikoto appears to have benefited
from revival of interest in handmade design and are increasingly
discovering ways to reach new audiences on digital platforms.



“Kamikoto blades have cut down cultural barriers. We’re seeing
incredible interest in our knives and adding new clients every day. It’s
reassuring to do well, but we have been making knives for a while, and
our approach has always been to focus on perfection, creating a fine
blade that our clients will be happy with. A handmade knife has a
special feel that doesn’t compare with your usual store bought knife.
And they keep for generations.”



https://kamikoto.com/



Facebook



Instagram



YouTube



About Kamikoto



Kamikoto is the original manufacturer of Japanese Niigata steel knives.
Up until recently, Niigata steel knives have not been widely available
to the general public, but for a few discerning chefs who have imported
Niigata steel knives for use in their restaurants around the world.
Kamikoto stays true to Niigata’s century-old legacy to create knives of
unmatched quality and beauty.


Contacts


Kamikoto
Kimberly, +815058062758
Kim@kamikoto.com

Panasonic Donates a Total of 1,584 Solar Lanterns to South … 2017年03月24日 20時06分


100 Thousand Solar Lanterns Project has achieved over 80,000
donations in total


JOHANNESBURG--(BUSINESS WIRE)--#ABetterLifeABetterWorld--Since 2012, Panasonic Corporation has been working on the 100 Thousand
Solar Lanterns Project, a project that aims to donate a total of 100
thousand solar lanterns to the world's non-electrified areas by 2018,
which is the centennial of Panasonic's foundation. As part of the
effort, the company donated a total of 1,584 solar lanterns for the
first time to three nonprofit organizations (NGOs) working in the three
countries of the Republic of South Africa, Kingdom of Swaziland, and
Kingdom of Lesotho. Today, a donation ceremony was held at the Nelson
Mandela Foundation in South Africa.








The donation ceremony, held by the Nelson Mandela Foundation in South
Africa, was attended by government officials from the Republic of South
Africa and Shigeyuki Hiroki, Ambassador of Japan in the Republic of
South Africa.



Shigeyuki Hiroki said in his speech that “We expect to further promote
more effective use of donated solar lanterns in these three countries as
a promising renewable energy.”



Sello Hatang, CEO of the Nelson Mandela Foundation, noted in his speech
that 2018 would mark the 100th birthday of Nelson Mandela himself and
said that “We are challenging to change the quality of living in South
Africa. The lighting would contribute to improve daily life. The
Foundation supports Panasonic's solar lantern project activities and
helps people's better living by the donations of the lanterns to
non-electrified areas.”



At present, approximately 1.2 billion people are living in areas without
electricity*, which accounts for about 16% of the world population, of
which approximately 600 million people are in African countries.
Although many households in these areas without electricity use kerosene
lamps for lighting, its smoke poses a health hazard and exposes people
to the risk of fire.



By utilizing solar lanterns, children will be able to learn safely and
women's groups can engage in activities that create income at night in
the community, which will help them improve their lives and help a
sustainable society. Moreover, this reduces the economic burden of fuel
purchase costs.



In order to contribute to resolving these social issues, Panasonic has
been promoting corporate social responsibility (corporate citizenship
activities) by proactively using the company's core technologies and
products, and as part of this, has been implementing the 100 Thousand
Solar Lanterns Project. This donation activity is an initiative to
contribute to the global goals of Poverty, Health Care and Welfare,
Education, Energy, etc. that constitute the Sustainable Development
Goals (SDGs) put into effect by the United Nations in 2016.



Through this project, the company has donated a total of approximately
81,000 units to 19 countries so far. In Africa, about 15,000 units have
been donated already to 10 countries through international organizations
and NGOs. This donation to three African countries now makes the total
of donated lanterns approximately 83,000 units to 22 countries, and
among them, about 16,000 units have been delivered to 13 African
countries.



In addition, at the Sasol Solar Challenge, a solar car race held in
South Africa last year, a solar car team from Tokai University equipped
with Panasonic's solar cell module HIT(R) and a high-capacity
lithium-ion battery finished second after completing 4,544.2 km.



Panasonic will accelerate this activity until 2018, in order to deliver
a better life to the people living in the regions without electricity
through the 100 Thousand Solar Lantern Project utilizing the company's
core products and technologies.



*Source: International Energy Agency World Energy Outlook 2016



Donations destination organization
Republic
of South Africa: Nelson Mandela Foundation
Kingdom of Lesotho:
Lesotho Catholic Bishops Conference
Kingdom of Swaziland: All Out
Africa Foundation



100 Thousand Solar Lanterns Project
Starting
with the donation in Myanmar in 2011, Panasonic has donated more than
80,000 solar lanterns to 19 countries, mainly emerging and developing
countries in Asia and Africa. It has been reported that the bright light
of solar lanterns facilitates medical, educational and economic
activities at night and it eliminates a health hazard as well as
reducing the burden of households by reducing fuel costs.
Learn
more about the project at http://panasonic.co.jp/citizenship/lantern/



[Video] Panasonic Donates Solar Lanterns to South Africa, Swaziland, and
Lesotho
https://www.youtube.com/watch?v=eC_-Hs77gM0
[Photos]
https://goo.gl/photos/hLonBccURwaXn1e89



About Panasonic



Panasonic Corporation is a worldwide leader in the development of
diverse electronics technologies and solutions for customers in the
consumer electronics, housing, automotive, enterprise solutions and
device industries. Since its founding in 1918, the company has expanded
globally and now operates 474 subsidiaries and 94 associated companies
worldwide, recording consolidated net sales of 7.553 trillion yen for
the year ended March 31, 2016. Committed to pursuing new value through
innovation across divisional lines, the company uses its technologies to
create a better life and a better world for its customers. To learn more
about Panasonic: http://www.panasonic.com/global.



Related Links:
Feature Stories of 100 Thousand Solar
Lanterns Project | Panasonic Newsroom Global
http://news.panasonic.com/global/stories/solar_lantern_project/
100
Thousand Solar Lantern Project:
Homepage http://panasonic.net/sustainability/en/lantern/
Facebook
https://www.facebook.com/PanasonicSolarLantern






Contacts


Panasonic Corporation
Global Communications Department
Media
Promotion Office
presscontact@gg.jp.panasonic.com

Hitachi Zosen: Start of Kompogas Business in the U.S. 2017年03月24日 17時13分

OSAKA, Japan--(BUSINESS WIRE)--Hitachi
Zosen Corporation
(TOKYO:7004) has announced that Hitachi Zosen
Corporation (HZC) is to start first Kompogas
business in the U.S. jointly with Hitachi
Zosen Inova AG
(HZI), its wholly-owned subsidiary engaged in EPC and
service business of Energy from Waste (EfW).








Project SPC (Special Purpose Company) established by HZ group companies
constructs a Kompogas plant in San Luis Obispo County, California, and
will operate the plant generating electricity with compost sale for 20
years.



Summary of transaction:



HZI acquired the Kompogas EPC business of Axpo Kompogas Engineering AG
(Komeng) in 2014. In order to promote Kompogas business in the U.S.,
Kompogas SLO LLC being the Project SPC is established by capital
contribution of HZC group companies and starts the construction,
operation and maintenance of the plant. Investment to be recovered by
sale of electricity generated by gas engine and biogas produced from
plant and sale of compost as by-product of methanation process. For HZC
group companies, it is the first Kompogas business as well as the first
waste treatment plant as DBFOO (Design, Build, Finance, Own and Operate)
in the U.S.



The plant will handle around 30,000 tons of green waste and source
separated municipal organic waste from SLO County and produce 2’907’000
Nm3 biogas by Kompogas technology every year. Electricity
generated with biogas and gas engine is to be sold to the local electric
company which will be capable of supplying electricity up to some 600
households, and compost produced as residue will be sold separately.
This plant is maintained and operated by our group companies for 20
years.













































 

Summary of Kompogas business:

1. SPC:

 

Kompogas SLO LLC

2. Business:


Construction and operation of Kompogas plant

3. Total cost:


Approximately USD 22 million

4. Site:


San Luis Obispo County, California, U.S.A.

5. Construction period:


December 2016 to June 2018

6. EPC:


Hitachi Zosen Inova U.S.A. LLC

7. Operation period:


20 years from July 2018
































 

Summary of plant:

1. Capacity:

 

30,000 tons per annum (green waste and food waste)

2. Biogas generation:



2’907’000 Nm3 per annum



3. Gas Engine:


730kW

4. Residue:


20,000 tons per annum (solid compost and liquid fertilizer)

 


For the full text, please visit :
http://www.hitachizosen.co.jp/english/news/2017/03/002522.html




Contacts


Media Contact
Hitachi Zosen Corporation
Shinsaku
Sugimoto, +81-6-6569-0013
Katsuhiro Nagai, +81-3-6404-0802
Public
Relations Section
E-mail: PR_section@hitachizosen.co.jp
URL:
http://www.hitachizosen.co.jp/english/index.html



Intertrust and LINE Corporation to Host Conference Series o… 2017年03月24日 16時01分


First conference on “Exploring Technologies for Trusted Apps &
Services” will be held May 17,
2017 in Tokyo



SUNNYVALE, Calif.--(BUSINESS WIRE)--#appsecurity--Intertrust
Technologies Corporation
and LINE
Corporation
announced today that they will co-host a conference
series dedicated to furthering solutions for enhanced application
security and data privacy. The kickoff conference, hosted at the LINE
Auditorium, Shinjuku Miraina Tower 15F in Tokyo
, is entitled “LINE
and Intertrust Security Summit: Spring 2017 Tokyo” and will focus on
Exploring Technologies for Trusted Apps and Services. Experts from
academia and industry will present on leading research, technology and
market trends and real-world case studies for app security.



Intertrust is a pioneer in the field of trusted distributed computing
technologies. Intertrust’s Secure Systems group provides a host of
world-class solutions for application protection, distributed key
management and personalization. These products protect data and devices
around the world in areas ranging from consumer electronics to banking,
healthcare and automotive. LINE, Japan’s leading smart portal, is a
technology leader and supports hundreds of millions of users via their
mobile apps. To protect user privacy and data, LINE employs top-of-class
secure systems experts and partners with best-of-breed technology
companies like Intertrust.



“It is an honor to undertake an initiative like this with Intertrust, a
worldwide authority in software security,” said Takeshi Nakayama,
CPO/CISO of LINE Corporation. “The LINE messaging app and our many other
services are enjoyed across a broad range of consumer and corporate
settings, so enhancing information security is always a priority for us.
By holding this conference and actively working together with
Intertrust, we aim to make LINE’s information security stronger than
ever.”



“In LINE, we have found a great partner for Intertrust’s Secure Systems
division,” said Dave Maher, CTO of Intertrust.” Between LINE’S
formidable market presence in Asia and overall growth trajectory
world-wide, and Intertrust’s 25+ year history in developing technologies
for secure, distributed computing, we hope to bring value to the market.”



“LINE and Intertrust Security Summit: Spring 2017 Tokyo” will be held in
Tokyo on May 17, 2017. The second summit will be held in Silicon Valley
in Fall 2017. The summit will be by invitation only and will feature
distinguished speakers, including award-winning computer scientists with
expertise in secure systems and algorithms. More information on this
conference is available at: https://www.intertrust.com/company/events/line.



About Intertrust Technologies Corporation



Intertrust provides trusted computing products and services to leading
global corporations – from mobile and CE manufacturers and service
providers to enterprise software platform companies. These products
include the world’s leading digital rights management, software tamper
resistance and privacy-driven data platforms for ad tech, DNA storage
and IoT.



Founded in 1990, Intertrust is based in Silicon Valley, with regional
offices in London, Tokyo, Seoul and Beijing. The Company has a legacy of
invention, and its fundamental contributions in the areas of computer
security and digital trust are globally recognized. Intertrust holds
hundreds of patents that are key to Internet security, trust, and
privacy management components of operating systems, trusted mobile code
and networked operating environments, web services, and cloud computing.



Additional information is available at intertrust.com,
or follow us on Twitter or
LinkedIn.



About LINE Corporation



Based in Japan, LINE Corporation (NYSE:LN/TSE:3938) is dedicated to
“Closing the Distance,” operating a range of mobile services and
contents that connect people, information, and society. The LINE
messaging app was launched in June 2011 and has since grown into a
diversified Smart Portal platform, with its consumer and business
services used in more than 230 countries and territories.



Corporate website: https://linecorp.com/



LINE messaging app: https://line.me/




Contacts


DC2SFGroup LLC
Robin Buckley, 703-533-9805 or 703-201-3524 (mobile)
robin@dc2sfgroup.com
or
Varney
Business Communication
Leigh Anne Varney, 415-713-0713
la@varneybusiness.com

FDA Approves Symproic® (naldemedine) Once-Daily Tablets C-I… 2017年03月24日 11時50分

OSAKA, Japan & FLORHAM PARK, N.J. & STAMFORD, Conn.--(BUSINESS WIRE)--#PAINWeek--Shionogi
Inc.
and Purdue
Pharma L.P.
announced today that the U.S. Food and Drug
Administration (FDA) approved Symproic® (naldemedine) 0.2 mg
tablets C-II as a once-daily oral peripherally-acting mu-opioid receptor
antagonist (PAMORA) medication for the treatment of opioid-induced
constipation (OIC) in adult patients with chronic non-cancer pain.








Symproic is currently a Schedule II controlled substance because it is
structurally related to naltrexone. Shionogi Inc. submitted a petition
for the descheduling of Symproic, or removal of the controlled substance
classification, to the U.S. Drug Enforcement Administration (DEA), which
is currently under evaluation. Symproic will be jointly launched and
commercialized in the U.S. with Purdue Pharma and is expected to be
commercially available mid-summer.



“The FDA approval of Symproic provides a safe and effective therapy for
adult patients suffering from chronic non-cancer pain and struggling
with opioid-induced constipation,” said John Keller, President and Chief
Executive Officer, Shionogi Inc. “We believe Symproic will offer a new
therapeutic option to help reduce the needless suffering for those who
experience OIC. The launch of Symproic with Purdue Pharma this summer
will mark yet another milestone in our commitment to protect the health
and well-being of patients we serve.”



The FDA approval of Symproic was based on data from the COMPOSE program,
a global comprehensive development program comprised of clinical studies
conducted in adult patients with OIC and chronic non-cancer pain. It was
comprised of three studies: COMPOSE I, COMPOSE II and COMPOSE III.
COMPOSE I and II were 12-week, multicenter, randomized, double-blind,
placebo-controlled, parallel-group studies, while COMPOSE III was a
52-week, randomized, double-blind, placebo-controlled, long-term safety
study.



“By entering this exciting new therapeutic area with Shionogi Inc., we
have the opportunity to further help patients with chronic non-cancer
pain by offering more comprehensive care to both patients and doctors,”
said Mark Timney, President and Chief Executive Officer, Purdue Pharma
L.P. “The approval of Symproic marks a significant advancement in our
partnership with Shionogi as well as the diversification of our product
portfolio.”



Please see Important Safety Information, including Warnings &
Precautions and Adverse Reactions below
.



About Opioid-Induced Constipation



Constipation is one of the most commonly reported side effects
associated with opioid treatment, including among patients with chronic
non-cancer pain.1 When opioids bind to specific proteins
called mu-opioid receptors in the gastrointestinal (GI) tract,
constipation may occur. Opioid-induced constipation (OIC) is a result of
increased fluid absorption and reduced GI motility due to opioid
receptor binding in the GI tract. OIC is defined as a change in bowel
habits that is characterized by any of the following after initiating
opioid therapy: reduced bowel movement frequency, development or
worsening of straining to pass bowel movements, a sense of incomplete
rectal evacuation, or harder stool consistency.2 In patients
with chronic non-cancer pain, the prevalence of OIC ranges from
approximately 40-50 percent.3,4,5,6 In a survey of 322
patients taking daily opioids for chronic pain, 33 percent of patients
missed, decreased or stopped opioid use to ease bowel movements.7



Indication



Symproic® (naldemedine) CII is an opioid antagonist indicated for the
treatment of opioid-induced constipation (OIC) in adult patients with
chronic non-cancer pain.



Important Safety Information about Symproic



Symproic is contraindicated in:




  • Patients with known or suspected gastrointestinal (GI) obstruction and
    patients at increased risk of recurrent obstruction, due to the
    potential for GI perforation.


  • Patients with a history of a hypersensitivity reaction to Symproic.
    Reactions have included bronchospasm and rash.



Warnings and Precautions



Cases of GI perforation have been reported with use of another
peripherally acting opioid antagonist in patients with conditions that
may be associated with localized or diffuse reduction of structural
integrity in the wall of the GI tract. Monitor for the development of
severe, persistent, or worsening abdominal pain; discontinue if this
symptom develops.



Symptoms consistent with opioid withdrawal, including hyperhidrosis,
chills, increased lacrimation, hot flush/flushing, pyrexia, sneezing,
feeling cold, abdominal pain, diarrhea, nausea, and vomiting have
occurred in patients treated with Symproic.



Patients having disruptions to the blood-brain barrier may be at
increased risk for opioid withdrawal or reduced analgesia. Take into
account the overall risk-benefit profile when using Symproic in such
patients. Monitor for symptoms of opioid withdrawal in such patients.



Drug Interactions



Avoid use with strong CYP3A inducers (e.g. rifampin, carbamazepine,
phenytoin, St. John’s Wort) because it may reduce the efficacy of
Symproic.



Avoid use of Symproic with another opioid antagonist due to potential
for additive effect and increased risk of opioid withdrawal.



Use in Specific Populations



Symproic crosses the placenta and may precipitate opioid withdrawal in a
fetus due to the immature fetal blood-brain barrier. Symproic should be
used during pregnancy only if the potential benefit justifies the
potential risk. Because of the potential for serious adverse reactions,
including opioid withdrawal, in nursing infants, a decision should be
made to discontinue nursing or discontinue the drug, taking into account
the importance of the drug to the mother.



Controlled Substance



Symproic contains naldemedine, a Schedule II controlled substance.



Adverse Reactions



The most common adverse reactions with Symproic as compared to placebo
in clinical trials were: abdominal pain (8% vs 2%), diarrhea (7% vs 2%),
nausea (4% vs 2%), and gastroenteritis (2% vs 1%).



To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.



Please see complete U.S. Prescribing Information and Medication Guide at www.shionogi.com by
clicking here.



About Shionogi



Shionogi & Co., Ltd., is a Japanese pharmaceutical company with a
139-year history discovering and developing innovative therapies.
Shionogi Inc., the U.S. based subsidiary of Shionogi & Co., Ltd.,
continues this focus on the development and commercialization of high
quality medicines that protect the health and well-being of the patients
we serve. The company currently markets products in several therapeutic
areas including anti-infectives, pain and cardiovascular diseases. Our
pipeline is focused on infectious disease, pain, CNS and oncology. For
more details on Shionogi Inc., visit www.shionogi.com.
For more information on Shionogi & Co., Ltd., visit www.shionogi.co.jp/en.



About Purdue Pharma L.P.



Purdue Pharma is a privately-held pharmaceutical company and is part of
a global network of independent associated companies that is known for
pioneering research in chronic pain and opioids with abuse-deterrent
properties. The company’s leadership and employees are committed to
providing healthcare professionals, patients and caregivers quality
products and educational resources to support their proper use. Purdue
Pharma is engaged in the development, production and distribution of
both prescription and over-the-counter medicines and hospital products.
With Purdue Pharma’s expertise in drug development, commercialization
and life-cycle management, the company is diversifying in high-need
areas to expand through strategic acquisitions and creative
partnerships. For more information, please visit www.purduepharma.com.



REFERENCES



1 Sehgal N, Colson J, Smith HS. Chronic pain treatment with
opioid analgesics: benefits versus harms of long-term therapy. Expert
Rev Neurother
. 2013;13:1201-1220.



2 Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN,
Mawe GM. Emerging treatments in neurogastroenterology: a
multidisciplinary working group consensus statement on opioid-induced
constipation. Neurogastroenterol Motil. 2014; 26: 1386-1395.



3 Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in
chronic noncancer pain: systematic review of efficacy and safety. Pain.
2004;112:372–80.



4 Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side
effects in chronic opioid users: results from a population based survey. Aliment
Pharmacol Ther
. 2008;27(12):1224-1232.



5 Brown RT, Zuelsdorff M, Fleming M. Adverse effects and
cognitive function among primary care patients taking opioids for
chronic nonmalignant pain. J Opioid Manag.2006;2(3):137–146.



6 Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid
induced bowel disorders and narcotic bowel syndrome in patients with
chronic non-cancer pain. Neurogastroenterol Motil.
2010;22(4):424-430.



7 Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T,
Williamson R. The prevalence, severity, and impact of opioid induced
bowel dysfunction: Results of a US and European Patient Survey (PROBE
1). Pain Med. 2009; 10:35-42.


Contacts


Shionogi Inc.
Media
Lindsay N. Bohlander, PharmD,
+1-973-665-4245
Office: +1-973-307-3718
Lindsay.bohlander@shionogi.com
or
Purdue
Pharma L.P.
Catherine London
Office: +1-203-588-7530
Catherine.London@pharma.com

GA-ASI Announces Japanese Collaboration at “Japan Drone” 2017年03月24日 03時12分

SAN DIEGO & TOKYO--(BUSINESS WIRE)--General Atomics Aeronautical Systems, Inc. (GA-ASI), a leading
manufacturer of Remotely Piloted Aircraft (RPA) systems, radars, and
electro-optic and related mission systems solutions, today announced
during a briefing at the Japan Drone expo in Makuhari Messe, Chiba,
Japan, that it has executed a research collaboration agreement with a
consortium of Japanese industry, government, and academia groups to
accelerate operational approval for Medium-altitude Long-endurance
(MALE) RPA to fly in non-segregated Japanese civil airspace.




“The expertise arising from this collaboration in air traffic control,
communications technology, and operations will help drive our efforts to
validate Japanese airspace integration concepts for our Guardian
aircraft and other RPA,” said David R. Alexander, president, Aircraft
Systems, GA-ASI. “Local partnerships and their contributions in gaining
RPA acceptance in Japanese civil airspace is the first major step in
validating these concepts.”



The partnership seeks to establish the first civil MALE RPA flight
approval in Japan and examine its utility for public and commercial
operations. As a nation surrounded by sea and frequently impacted by
natural disasters such as earthquakes, tsunamis, and typhoons, Japan is
a country in strong need of resilient situational awareness and
communication capabilities. RPA such as Guardian are expected to play a
critical role in fulfilling these needs.



“We believe that it’s important to explore a framework that will allow
the full potential of RPA efficacy on missions to be maximized so that
it can contribute to humanitarian efforts such as disaster relief and
border protection to support Japan’s social priorities,” said Nobuyuki
Otsubo, director of strategic development, GA-ASI.



GA-ASI’s briefing at Japan Drone highlighted Japan’s significant need
for surveillance of the area around Japan. Japan Coast Guard, for
example, has an area 12 times the size of Japan that it is responsible
for. This area includes coverage of exclusive economic zones, search and
rescue, and immediate disaster relief. Guardian is an aircraft
specifically designed to provide the kind of coverage and information
that is critical for Japan today. It represents a multi-agency solution
for a multi-domain challenge. GA-ASI is working with several agencies in
Japan to be able to perform a demonstration of its technology later this
year.



The long-term goal of this collaboration is to fly the GA-ASI-designed
Guardian in non-segregated Japanese airspace and to expand the RPA’s
mission capabilities. Currently, RPA airspace regulations do not exist
in Japan, and this new partnership will strive to become the pathfinder
program in doing so.



About GA-ASI



General Atomics Aeronautical Systems, Inc., an affiliate of General
Atomics, delivers situational awareness by providing remotely piloted
aircraft systems, radar, and electro-optic and related mission systems
solutions for military and commercial applications worldwide. The
company’s Aircraft Systems business unit is a leading designer and
manufacturer of proven, reliable RPA systems, including Predator® A,
Predator B/MQ-9 Reaper® and Predator B/MQ-9 Reaper Extended
Range (ER), Gray Eagle and Gray Eagle ER, Predator C Avenger®
and Avenger ER, Predator XP, and SkyGuardianTM and SeaGuardianTM.
It also manufactures a variety of solid-state digital GCS, including the
next-generation Advanced Cockpit GCS, and provides pilot training and
support services for RPA field operations. The Mission Systems business
unit designs, manufactures, and integrates the Lynx®
Multi-mode Radar and sophisticated Claw® sensor control and
image analysis software into both manned and remotely piloted aircraft.
It also focuses on providing integrated sensor payloads and software for
Intelligence, Surveillance and Reconnaissance (ISR) aircraft platforms
and develops high energy lasers, electro-optic sensors, and
meta-material antennas. For more information, please visit www.ga-asi.com.



Reaper, Predator, Avenger, Lynx, and Claw are registered trademarks and
SkyGuardian and SeaGuardian are trademarks of General Atomics
Aeronautical Systems, Inc.




Contacts


General Atomics Aeronautical Systems, Inc.
Melissa Haynes, +1 (858)
524-8108
asi-mediarelations@ga-asi.com

Research and Markets Has Announced the Launch of Their Tesc… 2017年03月24日 00時10分

DUBLIN--(BUSINESS WIRE)--The new research portal is an invaluable resource for anyone seeking
company research on Tesco
and their activities, providing comprehensive research on their market
position, competitor activity and their future outlook within the retail
industry.




Tesco is the UK’s leading online grocery shopping service and has become
an active player in the B2C e-commerce market. According to one report
featured on the portal, Top
5 Country B2C E-Commerce Sales Forecasts: 2016-2020
, China has the
largest and fastest-growing B2C E-Commerce sales, followed by the USA,
the UK, Japan and Germany. Of the top 5, only China is predicted to
maintain growth rates above 20% over the forecast period, as a declining
growth rate is characteristic of these world leaders. This is especially
so in the mature market of the UK, the global leader in B2C E-Commerce’s
share of total retail.



“The portal provides visitors with unparalleled access to company
research on Tesco, enabling them to track the company’s performance and
impact on the various markets in which it is currently engaged,” says
Ross Glover, CEO of Research and Markets.



For more information visit http://www.researchandmarkets.com/companies/tesco-plc&cid=3gtzbf



About Research and Markets



Research and Markets is the world's leading market research store.



With more than 1.5 million research resources, we deliver the largest
collection of business information products on the market. We offer the
most in-depth market analysis across a multitude of industries. Our
products provide clients with an unrivalled understanding of their
chosen market. No matter how specialist your field, we have the insights
and market data to help you make efficient and effective decisions.


Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Vallourec 社が知財管理の統合及び合理化を促進するためにANAQU… 2017年03月23日 23時00分


大幅な効率化と費用削減を実現する新しいソフトウェア


BOSTON--(BUSINESS WIRE)--(ビジネスワイヤ) -- 本日、知的財産管理と特許分析に関するソフトウェアおよびサービスにおいて世界をリードする Anaqua,
Inc.
は、エネルギー関連産業用の高品質鋼管を供給する世界的メーカーの Vallourec 社と、Vallourec
社所有の特許・商標のグローバル管理業務を行うためにANAQUA 8.6
統合型知財管理プラットフォームの導入に関する複数年契約を締結したことを発表しました。




既に多数の特許と商標を有し、今後もその数の増加が予想される Vallourec
社では、知財管理業務の効率化、処理時間の短縮、費用削減を図るため、知財管理システムのアップグレードを行い、1つのプラットフォーム上で自社知財の全てを統一的に管理する方法を探っていました。



Vallourec
社知的財産管理部長のリチャード・マルソレー氏は「当社では、世界的なレベルで知的財産管理の効率化が図れ、より利便性が高く、より合理化されたワークフローを搭載した、Webベースの統合型知財管理ソリューションを求めていました。ANAQUA
8.6は、これら全ての要件を満たしていました。」と述べています。



Anaqua の欧州地区担当ジェネラルマネージャーであるジョナサン・ニューコム氏は
「我々は、イノベーションと技術におけるリーダーであり続けようとするVallourec
社のような先進的な企業とパートナーシップを組めることを嬉しく思います。 ANAQUA 8.6 の導入により、Vallourec
社ではイノベーションのプロセス管理が改善され、世界各国に所有する貴重な知的財産の状況がより簡単に把握できるようになるでしょう。」と語っています。



ANAQUA について
Anaquaは、知的財産をより競争的優位にするために企業や法律事務所を支援する会社です。Anaquaのソフトウェアプラットフォームは、ビッグデータアナリティクスに基づく知見、重要なツール類、ベストプラクティスのワークフローやサービスを1つの効率的で知的な環境に統合しているため、より効率的に知財管理業務を行い、より迅速に、より適切な決定を下すことができます。世界的な有名ブランドや最も革新的な製品の多くが、Anaquaのプラットフォーム上で概念化され、評価され、権利化され、収益化されています。The
Coca-Cola Company、Ford Motor Company、 Kimberly-Clark、British American
Tobacco 各社の知財管理のリーダー達によって2004年に設立された Anaqua
は、米国ボストンに本社を置く非公開企業で、北米の他、欧州とアジアの各国で事業を展開しています。当社の詳細についてはhttp://www.anaqua.comをご覧
ください。



VALLOUREC 社について
Vallourec
社は、エネルギー関連産業向け高品質鋼管の世界的メーカーであり、その製品は過酷な環境下の油田・ガス田、次世代電力発電プラント、困難な状況下での建築プロジェクト、高性能機器など、高度な技術を要する産業で使用されています。Vallourec
社のパイオニア精神と最先端を行く研究開発は、現在に至るまで様々な新技術を開拓してきました。世界20カ国以上に散らばる約2万人の従業員は、鋼管の供給に止まらず、イノベーティブで安全性に優れ、かつ競争力のあるインテリジェントなソリューションを届け、あらゆるプロジェクトの実現に向けて、顧客と一体となり情熱を持って取り組んでいます。Vallourec
社の詳細については http://www.vallourec.comをご覧
ください。




Contacts


Anaqua, Inc.
Tony Catinella, 617-375-2626
Public Relations
Manager at Anaqua
acatinella@Anaqua.com



NTT Solmare Releases a NEW Title from the "Shall we date?" … 2017年03月23日 21時00分

OSAKA, Japan--(BUSINESS WIRE)--NTT Solmare Corporation (Headquarters: Osaka, Japan; President: Akira
Tomana, hereafter referred as “NTT Solmare”) is thrilled to announce the
release of a social-based dating sim game, “Sengoku Darling -Choose your
destination-”. The game is available worldwide for both iOS and Android
devices starting today, March 23, 2017.







Originally released by GignoSystem Japan as “Iza, Shutsujin! Koi Ikusa
Dai Ni Maku”, a Japanese-only game for mobile and portable platforms,
“Sengoku Darling -Choose your destination-” has been translated into
English for people abroad to enjoy. “Sengoku Darling” depicts a
bittersweet romance between the heroine and famous historical warlords
during the Sengoku Period. These stories are now globally accessible to
iOS/Android users for $4.99 per character at the NTT Solmare App Store
found here: http://shallwedate.jp/sd



“This time, we bring you new features, such as character motion and
story effects. We hope these updates could give our users a good
surprise and better enjoyment.”, said Senior Vice President, Yasuhiro
Manabe.



Story Introduction



The story takes place in the Sengoku Period, a warring era of
never-ending social upheaval and military conflict. You, the heroine, is
a princess of a small yet peaceful province. With your father in bad
health and no son to take over the province, you are told to go on a
journey to see through the world around you and find a strong province
to ally with. For that, you head to the capital city of Kyoto together
with your guard, Kojiro Sasaki, for information and chance to meet with
strong warlords.
Life outside your own castle is not easy, but as
you spend your life in the foreign land of your choice, you get to know
more of the warlords living there. And eventually, the seed of love
blooms into a transient flower...



Price



Each Character’s story highlights and Prologue: Free.
Main story:
500 Coins ($4.99 (USD)) per character.
Extra Story: 100 Coins
($0.99 (USD)) per story.
*Above is the price listed in US iTunes
App Store and Google Play Store.
*Players purchasing from countries
other than US will be charged an equivalent amount of the price above.



Release Date:



March 23, 2017 (PST)



Language



English



Supported OS versions:



*Android: 4.1 or later
*iOS: 7.0 or later



How to access:



Access the URL below from a smartphone or other mobile device.
URL: http://shallwedate.jp/sd



Social Networking Sites



Shall we date? Official: http://www.nttsolmare.com/shallwedate/
Facebook:
https://www.facebook.com/ShallWeDate.NTTSolmare



About NTT Solmare Corporation:



Game apps which NTT Solmare has released under the brand name of “Shall
we date?” have been enjoyed in 166 countries, with more than 26 million
downloads from all over the world. “Shall we date?” games have received
praise from their fans, having an average review score of 4.4/5.0 in
iTunes App Store as of March 2017.



NTT Solmare Corporation will continue providing our customers with a
great satisfaction in creating advanced services from the customers’
perspective, holding the corporate mission: “We, NTT Solmare, offer new
kinds of surprise and plenty of excitement to our customers,
contributing to enrichment of our society.”



(URL: http://www.nttsolmare.com/e/)




Contacts


Press Contact:
NTT Solmare Corporation
Mariko Kanamoto
/ Kenji Tanaka, +81-6-6228-8861
Game Department



バーチャストリームが基幹アプリケーション向けエンタープライ… 2017年03月23日 19時57分


デルテクノロジーズとの提携により、地域でのサービス提供を強化


シドニー--(BUSINESS WIRE)--(ビジネスワイヤ)-- 企業レベルのクラウドサービスを提供する企業でデルテクノロジーズの事業部門のバーチャストリームは本日、当社の基幹アプリケーション向けエンタープライズクラウドプラットフォーム/サービスが、オーストラリアと日本を含むアジア太平洋地域で提供可能になったと発表しました。このサービスには、バーチャストリームの革新的なクラウド技術と、当社独自の従量課金請求モデルが含まれます。




当地域では、エンタープライズクラウドサービスのニーズが高まっています。IDCが公表した調査結果によると、2020年までに「IDCは日本を含むアジア太平洋地域で、クラウドシステム・インフラサービスによる売上高が129億ドルに達する」と予測しています。



IDCのシニアバイスプレジデントでチーフアナリストのフランク・ジェンス氏は、次のように述べています。「アジア太平洋地域には、企業レベルのクラウドサービスに対する膨大な累積需要があります。これは、諸組織が事業を世界規模で急速に拡大しながら、既存の「記録のシステム」をクラウドに移行する際の複雑性を管理したいと考えているためです。それにデータ主権などの地域的ニーズが加わると、プロバイダーの活動分野が非常に限られてきます。」



バーチャストリームは、オーストラリアとニュージランド(ANZ)地域の顧客に当社のエンタープライズクラウドプラットフォームを提供します。これは商取引、顧客対応、企業の生産性において不可欠な基幹アプリケーション向けに特別に作ったプラットフォームです。バーチャストリームは、オーストラリア国内の企業と公共部門の両ニーズに対応できるよう、シドニーとキャンベラにクラウドの拠点を展開しました。バーチャストリームは日本の国内ICTプロバイダーと共に日本への事業拡張を最近発表していますが、今回の拡張はそれに続くものです。



バーチャストリームのサイモン・ウォルシュ最高執行責任者(COO)は、次のように述べています。「当社はアジア太平洋地域のお客さまのために、最も困難なデジタル変革プロジェクトに取り組む体制が整っています。当社の各国での提携関係、当社のクラウドプラットフォームの強み、エンタープライズクラウド分野の深い専門性、そしてデルテクノロジーズとの関係を組み合わせることで、クラウドを活用して業務を迅速に変革・拡張できるよう、これまでにない機会を同地域の企業に提供できるようになります。」



バーチャストリームがアジア太平洋地域で事業拡張を続ける中、デルテクノロジーズとの提携は成功の方程式に欠かせない要素となります。



Dell
EMCオーストラリア/ニュージランドのバイスプレジデントを務めるマーク・フィオレットは、次のように語っています。「バーチャストリームとDell
EMCのクラウドソリューションは、諸組織がANZでエンタープライズクラウドにアプローチするための新たな方法を提供します。このプラットフォームは従量課金制の費用便益をもたらすほか、セキュリティー、コンプライアンス、アプリケーション性能、災害復旧力を向上できます。基幹的な記録システムのクラウドへの移行は複雑で、特別な専門知識が必要です。当社のお客さまが本当の意味で環境を変革するには、マルチクラウド戦略が必要です。Dell
EMCは、バーチャストリームと当社のサービスプロバイダーエコシステムの間にあって、企業と公共部門のお客さまが自組織のデジタル変革に取り組む際に必要な選択肢を提供する上で、理想的な立場にあります。」



バーチャストリームによる企業のIT資産の変革に関する詳細については、下記のリンクをクリックしてください。




バーチャストリームについて



デルテクノロジーズの事業部門であるバーチャストリームは、企業レベルのクラウドサービスを提供する企業で、基幹アプリケーションをクラウドに移行し、運用しようとする世界中の組織に信頼されています。企業、サービスプロバイダー、政府機関にとって、バーチャストリームのxStream管理プラットフォームとサービスとしてのインフラストラクチャー(IaaS)は、プライベート、パブリック、ハイブリッドを問わず、クラウド上の複雑な実稼動アプリケーションで求められるセキュリティー、コンプライアンス、パフォーマンス、効率、従量課金の要件に対応します。



本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。




Contacts


Virtustream, Inc.
Jennifer Brenner, 713-409-5627
Jennifer.Brenner@virtustream.com

Ullink、MiFID II取引報告ソリューションを発表 2017年03月23日 17時24分


企業はマルチアセットソリューションを活用して2018年実施のポストトレード透明性ルールに準拠することが可能に


ロンドン--(BUSINESS WIRE)--(ビジネスワイヤ) -- 金融業界向け電子取引/接続ソリューションを提供する世界的企業であるUllink(ユーエルリンク)は、MiFID
II準拠の取引報告ソリューションを発表しました。このソリューションを利用すれば、クライアントは規制要件をクリアして、報告書の正確性を向上させ、タイムリーなデータ収集が可能となります。



取引報告に関する改革は、MiFID
IIの要となっています。新規則の下では、適格金融商品(株式と非株式の両方)のあらゆる取引の詳細を、できるだけリアルタイムで市場参加者に公開する必要があります。実際のところ、一部の商品では、これは取引後1分以内であることを意味します。



この動きが市場参加者に重大な課題を突き付けていることは、WBRリサーチが最近実施した調査の中で解説されています。欧州の株式トレーダー150人を対象に実施した本調査では、回答者の37%がMiFID
II改革による最大の影響が予想される要因として「ポストトレーディング問題」を挙げています。



Ullinkは、15年以上にわたって資本市場の企業にトレーディングソリューションを提供してきた経験を生かして、クロスアセットクラスの取引報告における要件に対処するための自動化ソリューションを構築するために、ESMA仕様の分析の処理速度を上げてきました。本ソリューションは、認可公表アレンジンメント(APA)の下で運営している複数の取引報告場において、報告ステータスと報告書修正/取り消しの機能を提供する一元管理ダッシュボードとして使用されます。本ソリューションには、取引報告書作成のコストを最適化するビジネスルールに基づいてAPAを選択するスマート・レポート・ルーティング(Smart
Report Routing)ロジックが搭載されています。



Ullinkの最高製品責任者(CPO)を務めるリチャード・ベントレーは、次のように述べています。「MiFID
IIの実施が近づくにつれ、企業において、過不足のある報告書を作成する可能性を排除するために、取引報告書の作成で規則を正しく適用できる自動化ソリューションを導入しなければならないという圧力が高まっています。またAPAの状況が変化していることから、複数のフロントオフィス受注管理システムからの入力処理をすべてのアセットクラスに対して実行できる一元管理ソリューションに注目が集まっています。新しいユーエルリンク・トレード・レポーティング(Ullink
Trade
Reporting)ソリューションは、Ullinkのポートフォリオに追加された強力なソリューションであり、取引後ワークフローに対する新規制の負担を軽減することを目的としています。



-以上-



本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。




Contacts


CONTACT:
ULLINK
Mireille Adebiyi
Marketing
& Communications Director
Tel.: +33 1 49 95 30 00
mireille.adebiyi@ullink.com
www.ullink.com
or
COGNITO
Tel:
+44 (0)20 74269420
Oliver Mann
Oliver.Mann@cognitomedia.com
or
Paul
Bowhay
Paul.Bowhay@cognitomedia.com



KKR Completes Tender Offer for Calsonic Kansei 2017年03月23日 17時02分

TOKYO & SAITAMA, Japan--(BUSINESS WIRE)--Global investment firm KKR
and leading Japanese automotive components manufacturer Calsonic
Kansei Corporation
(“CK”) today announced the completion of a tender
offer by CK Holdings Co., Ltd. (the "Offeror"), an entity owned by KKR
investment funds, for all the existing common shares of CK. 95.21% of
the existing common shares has been tendered through the tender offer
and will be acquired by the Offeror. In the tender offer, Nissan Motor
Co., Ltd., CK’s largest shareholder, tendered its approximate 41%
holding of CK's common shares. After the acquisition of the tendered
shares, the Offeror will implement a series of procedures to acquire the
remaining common shares of CK.







CK is a leading supplier of automotive components including cockpit
systems, thermal systems, exhaust systems and advanced electronic
products. Nissan-Renault-Mitsubishi Alliance is the primary customer for
CK, which also supplies a variety of other automotive groups including
Isuzu, Mazda, VAG, and General Motors.



Mr. Hiroshi Moriya, President and CEO, Calsonic Kansei Corporation,
said, "We are excited to work alongside the KKR team given their
extensive global expertise in the auto, manufacturing and services
sectors, as well as their shared goals for our business. Through this
partnership, we look forward to seeing Calsonic Kansei grow by reaching
new markets and providing innovative new products to customers
worldwide.”



Mr. Hiro Hirano, Member of KKR and CEO of KKR Japan, said, "Calsonic
Kansei is a world-class leader in the auto-parts sector with excellent
potential for growth. We are delighted to have successfully completed
this transaction, and in the years to come, we will support the company
and its employees in achieving their ambitions to make this high-caliber
business even better.”



KKR makes its investment predominantly from its Asian II Fund.



About Calsonic Kansei



Calsonic Kansei is an automotive company, and operates a global network
across the world by having its global headquarters in Japan, and its
management operations in the Americas, Europe, China and Asia. In
addition, there are development operations in Japan, U.S.A., Mexico,
U.K., France, China, Thailand and India, and 78 production sites
throughout the world, from which products can be supplied to all
customers in an optimal manner.



More than 20,000 employees of the company are striving to provide
appealing products to customers with great teamwork across national
boundaries. For additional information about Calsonic Kansei
Corporation, please visit Calsonic Kansei’s website at www.calsonickansei.co.jp/english/index.html.



About KKR



KKR is a leading global investment firm that manages investments across
multiple asset classes including private equity, energy, infrastructure,
real estate, credit and hedge funds. KKR aims to generate attractive
investment returns by following a patient and disciplined investment
approach, employing world‐class people, and driving growth and value
creation at the asset level. KKR invests its own capital alongside its
partners’ capital and brings opportunities to others through its capital
markets business. References to KKR’s investments may include the
activities of its sponsored funds. For additional information about KKR
& Co. L.P. (NYSE:KKR), please visit KKR’s website at www.kkr.com
and on Twitter @KKR_Co.




Contacts


Calsonic Kansei
CSR/Public Relations & IR Group
+81-48-660-2161
or
KKR
Asia Pacific
Anita Davis, +852 3692-7335
anita.davis@kkr.com
or
KKR
New York
Kristi Huller, +1 212-230-9722
kristi.huller@kkr.com
or
For
KKR Japan

Ashton Consulting
John Sunley, +81-3-5425-7220
jas@ashton.jp
or
Brendan
Jennings, +81-3-5425-7220
b.jennings@ashton.jp



KKR Completes Tender Offer for Hitachi Koki 2017年03月23日 12時47分

TOKYO--(BUSINESS WIRE)--Global investment firm KKR
and leading power tool and life science equipment manufacturer Hitachi
Koki Co., Ltd.
(“Hitachi Koki” or the “Company”) today announced the
completion of a tender offer by HK Holdings Co., Ltd. (the "Offeror"),
an entity owned by KKR investment funds, for all the existing common
shares and stock acquisition rights of Hitachi Koki. Approximately
89.79% of the existing common shares and stock acquisition rights have
been tendered through the tender offer and will be acquired by the
Offeror. In the tender offer, Hitachi, Ltd., Hitachi Koki’s largest
shareholder, tendered its approximate 40.25% holding of Hitachi Koki
common shares and Hitachi Urban Investment, Ltd. tendered its
approximate 10.90% holding of Hitachi Koki common shares. After the
acquisition of the tendered shares, the Offeror will implement a series
of procedures to acquire the remaining common shares, such that Hitachi
Koki will become a wholly-owned subsidiary of the Offeror.







Hitachi Koki is a leading supplier of high-performance, high-quality
power tools and life science equipment, competing in the global
marketplace to introduce cordless technology to a wider range of power
tool products and applications. The Company is actively pursuing
expansion in global markets and acquired German power tool company
metabo Aktiengesellschaft in March 2016. The Company also formed a
strategic alliance with major North American hardware chain Lowe’s
Companies, Inc. in 2015.



Mr. Osami Maehara, President & Representative Executive officer of
Hitachi Koki Co., Ltd., said, "We welcome KKR as a world‐class investor
to support Hitachi Koki’s growth as an independent company. KKR has a
great track record of helping Japanese companies enhance their
innovation and scope as a stand-alone business, and we look forward to
capturing new opportunities in the global power tools industry alongside
KKR’s team globally and in Japan."



Mr. Hiro Hirano, Member of KKR and CEO of KKR Japan, said, “We are
delighted to have successfully completed this transaction and are
extremely excited to work with Hitachi Koki to explore growth
opportunities and build on its success as a globally recognized and
trusted brand in the power tools industry. Through the combination of
Hitachi Koki’s strengths in technological development and KKR’s global
network and management expertise, I am confident we can accelerate
Hitachi Koki’s growth strategy and further improve customer value.”



KKR makes its investment predominantly from its Asian II Fund.



About Hitachi Koki



Hitachi Koki is a global manufacturer and supplier of power tools and
life science instruments for the professional market. Its fundamental
management principle is to contribute to society by providing
sophisticated, high quality products and services with a high degree of
customer satisfaction. Hitachi Koki generates 77%1 of its
sales and manufactures 93%2 of its products outside Japan.



1 Q3 FY2016 results (cumulative)
2 Unit basis



About KKR



KKR is a leading global investment firm that manages investments across
multiple asset classes including private equity, energy, infrastructure,
real estate, credit and hedge funds. KKR aims to generate attractive
investment returns by following a patient and disciplined investment
approach, employing world‐class people, and driving growth and value
creation at the asset level. KKR invests its own capital alongside its
partners’ capital and brings opportunities to others through its capital
markets business. References to KKR’s investments may include the
activities of its sponsored funds. For additional information about KKR
& Co. L.P. (NYSE:KKR), please visit KKR’s website at www.kkr.com and
on Twitter @KKR_Co.




Contacts


Hitachi Koki
Public Relations Strategy Office
03-5783-0601
ir@hitachi-koki.co.jp
or
KKR
KKR
Asia Pacific
Anita Davis, +852 3602-7335
anita.davis@kkr.com
or
KKR
New York
Kristi Huller, +1 212-230-9722
kristi.huller@kkr.com
or
For
KKR Japan

Ashton Consulting
John Sunley, +81-3-5425-7220
jas@ashton.jp
or
Brendan
Jennings, +81-3-5425-7220
b.jennings@ashton.jp



Launching the Official Japan Heritage BORDER ISLANDS App. 2017年03月23日 10時00分


Add to the Enjoyment of your Trip to Nagasaki’s
Japan Heritage Islands!

Featuring
Route Information for All of the Islands’ Attractions, and an AR Ancient
Times Camera Function.

Can You
“Catch” the Local Mascot Characters with the Official App!?




NAGASAKI, Japan--(BUSINESS WIRE)--The Japan Heritage BORDER ISLANDS Promotion Council, which comprises the
Nagasaki Prefectural Government, the local governments of the cities of
Tsushima, Iki, and Gotō and Shin-Kamigoto Town, and other relevant
organizations, has launched an official app to enhance the sightseeing
experience of tourists in the Japan Heritage-designated Border Islands.




The app is packed with information and features to make your sightseeing
trip to Iki, Tsushima, and Gotō Islands even more enjoyable! Use the app
to learn more about the cultural properties on the islands and about
nearby facilities, find directions to your chosen destination, and take
photos with the AR camera. You are sure to find it useful.



Click here to download the smartphone/tablet app from the iOS (App
Store).
https://itunes.apple.com/us/app/japan-heritage-border-islands/id1209943141?&ls=1&mt=8
Click
here to download the smartphone/tablet app from Android (Google Play).
https://play.google.com/store/apps/details?id=com.kokkyonoshima.app



Special website here.
http://kokkyonoshima.com/eng




Contacts


Japan Heritage BORDER ISLANDS Promotion Council
Tomomi Nakao,
+81-95-895-2762

Virtustream Expands Enterprise Cloud Platform for Mission C… 2017年03月23日 07時00分


Partnership with Dell Technologies Helps to Bolster Regional Offering


SYDNEY--(BUSINESS WIRE)--Virtustream,
the enterprise-class cloud company and a Dell Technologies Business,
today announced that its enterprise cloud platform and services for
mission critical applications are now available in the Asia-Pacific
region including Australia and Japan. This offering includes
Virtustream’s innovative cloud technology and unique consumption billing
model.




The need for enterprise cloud services in the region is increasing.
According to published research, by 2020, “IDC predicts the Cloud
Systems Infrastructure Services revenue in Asia/Pacific including Japan
will reach $12.9 billion.”



“The pent up demand for enterprise-level cloud services in the
Asia-Pacific region is tremendous as organizations are eager to globally
scale their operations at a rapid pace; while also managing the
complexities of migrating their existing systems of record to the
cloud,” said Frank Gens, IDC senior vice president and chief analyst.
“Add to that regional needs such as data sovereignty, and it narrows the
playing field of providers significantly.”



Virtustream is bringing its enterprise cloud platform - built
specifically for the mission critical applications that are essential
for commerce, customer interaction, and enterprise productivity—to
customers in the Australia/New Zealand (ANZ) region. Virtustream has
established a cloud presence in Sydney and Canberra in order to serve
the needs of both the enterprise and public sectors within Australia.
This expansion comes on the heels of Virtustream’s recently announced
expansion in Japan with regional
ICT providers
.



“We are prepared to tackle the most challenging digital transformation
projects for our customers in Asia-Pacific,” said Simon Walsh, chief
operating officer, Virtustream. “Our local partnerships combined with
the strength of our cloud platform, deep expertise in the enterprise
cloud space and relationship with Dell Technologies will provide
businesses in the region with an unprecedented opportunity to utilize
the cloud to rapidly transform and scale their businesses.”



Virtustream’s partnership with Dell Technologies is a critical part of
its formula for success as it continues to expand in the Asia-Pacific
region.



“Virtustream and Dell EMC’s cloud solution will create new ways for
organisations to approach enterprise cloud in ANZ. The platform offers
the cost benefits of consumption billing, as well as increased security,
compliance, application performance and disaster recovery,” said Mark
Fioretto, vice president, Enterprise, Dell EMC Australia and New
Zealand. “The business of migrating mission-critical systems of record
to the cloud is complex and requires specific expertise. Our customers
require a multi-cloud strategy to truly transform their environments.
Between Virtustream and our service provider ecosystem, Dell EMC is
ideally positioned to provide enterprise and public sector customers
with the choice they need to digitally transform their organisations.”



To learn more about how Virtustream transforms enterprise IT estates,
click on the following links:




About Virtustream



Virtustream, a Dell Technologies business, is the enterprise-class cloud
company that is trusted by organizations worldwide to migrate and run
their mission-critical applications in the cloud. For enterprises,
service providers and government agencies, Virtustream’s xStream
management platform and Infrastructure-as-a-Service (IaaS) meets the
security, compliance, performance, efficiency and consumption-based
billing requirements of complex production applications in the cloud -
whether private, public or hybrid.




Contacts


Virtustream, Inc.
Jennifer Brenner, 713-409-5627
Jennifer.Brenner@virtustream.com

Alexion Submits Application in Japan for Soliris® (Eculizum… 2017年03月23日 05時05分

NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that it has
submitted an application to Japan’s Ministry of Labour and Welfare
(MHLW) to extend the indication for Soliris® (eculizumab)
as a potential treatment for patients with refractory generalized
myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR)
antibody-positive. The submission is supported by comprehensive data
from the Phase 3 REGAIN study.




“We look forward to working with the Japanese health authorities to
bring this potentially life-transforming treatment to patients in Japan
who are suffering and in urgent need of an effective therapy,” said
Martin Mackay, Ph.D., Executive Vice President and Global Head of R&D at
Alexion. “If approved, Soliris could be a critical step toward improving
the lives of patients with refractory gMG.”



Patients with AChR-positive refractory gMG represent an ultra-rare
population. Despite existing treatment options for gMG, these patients
continue to face severe complications, including difficulty walking,
talking, swallowing, and breathing normally. Exacerbations of their
disease may be life-threatening and require hospitalization and
intensive care.



If approved, Soliris would be the first and only complement inhibitor
for patients with refractory AChR-positive gMG in Japan. Alexion has
also submitted marketing applications in the U.S. and EU to extend the
indication for Soliris as a potential treatment for patients with
refractory gMG who are AChR-positive, which have been accepted by the
U.S. Food and Drug Administration (FDA) and validated by the European
Medicines Agency (EMA). Soliris has received Orphan Drug Designation
(ODD) for the treatment of patients with MG in the U.S. and EU, and for
treatment of patients with refractory gMG in Japan. Soliris is not
approved in any country for the treatment of patients with refractory
AChR-positive gMG.



About Refractory Generalized Myasthenia Gravis1-8



Refractory generalized myasthenia gravis (gMG) patients who are
anti-acetylcholine receptor (AChR) antibody-positive represent an
ultra-rare segment of patients with MG—a chronic, debilitating and
progressive autoimmune neuromuscular disease where the complement system
mediates a progressive, destructive inflammatory effect on the
neuromuscular junction. Patients with refractory AChR-positive gMG
experience severe morbidities and life-threatening complications despite
currently available MG therapies.



MG typically begins with weakness in the ocular muscles and often
progresses to the more severe and generalized form, known as gMG, to
include weakness of the head, neck, trunk, limb and respiratory muscles.
While most symptoms in patients with gMG are managed with conventional
therapies, 10% to 15% of patients are considered refractory—meaning they
do not respond to multiple conventional therapies and continue to suffer
profound muscle weakness throughout the body that can result in slurred
speech, impaired swallowing and choking, double vision, disabling
fatigue, shortness of breath due to respiratory muscle weakness,
immobility requiring assistance, frequent hospital and intensive care
unit admissions with prolonged stays, and periods of respiratory failure.



In patients with AChR-positive MG, the body’s own immune system turns on
itself to produce antibodies against AChR, a receptor located on muscle
cells in the neuromuscular junction (NMJ) and used by nerve cells to
communicate with the muscles these nerves control. The binding of these
antibodies to AChR activates the complement cascade which leads to the
destruction of the NMJ. As a result, the communication between nerve and
muscle is disrupted, which leads to a loss of normal muscle function.



Today, there are no approved therapies for the ultra-rare population of
patients suffering from refractory AChR-positive gMG.



About Soliris® (eculizumab)



Soliris is a first-in-class terminal complement inhibitor developed from
the laboratory through regulatory approval and commercialization by
Alexion. Soliris is approved in the U.S. (2007), European Union (2007),
Japan (2010) and other countries as the first and only treatment for
patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce
hemolysis. PNH is a debilitating, ultra-rare and life-threatening blood
disorder, characterized by complement-mediated hemolysis (destruction of
red blood cells). Soliris is also approved in the U.S. (2011), European
Union (2011), Japan (2013) and other countries as the first and only
treatment for patients with atypical hemolytic uremic syndrome (aHUS) to
inhibit complement-mediated thrombotic microangiopathy, or TMA (blood
clots in small vessels). aHUS is a debilitating, ultra-rare and
life-threatening genetic disorder characterized by complement-mediated
TMA. Soliris is not indicated for the treatment of patients with
Shiga-toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). For
the breakthrough medical innovation in complement inhibition, Alexion
and Soliris have received some of the pharmaceutical industry's highest
honors: the Prix Galien USA (2008, Best Biotechnology Product) and
France (2009, Rare Disease Treatment).



For more information on Soliris, please see full prescribing information
for Soliris, including BOXED WARNING regarding risk of serious
meningococcal infection, available at www.soliris.net.



Important Safety Information



The U.S. prescribing information for Soliris includes the following
warnings and precautions: Life-threatening and fatal meningococcal
infections have occurred in patients treated with Soliris. Meningococcal
infection may become rapidly life-threatening or fatal if not recognized
and treated early. Comply with the most current Centers for Disease
Control (CDC)’s Advisory Committee on Immunization Practices (ACIP)
recommendations for meningococcal vaccination in patients with
complement deficiencies. Immunize patients with meningococcal vaccines
at least two weeks prior to administering the first dose of Soliris,
unless the risks of delaying Soliris therapy outweigh the risk of
developing a meningococcal infection. Monitor patients for early signs
of meningococcal infections and evaluate immediately if infection is
suspected. Soliris is available only through a restricted program under
a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris
REMS, prescribers must enroll in the program. Enrollment in the Soliris
REMS program and additional information are available by telephone:
1-888-SOLIRIS (1-888-765-4747) or at www.solirisrems.com.



Patients may have increased susceptibility to infections, especially
with encapsulated bacteria. Aspergillus infections have occurred in
immunocompromised and neutropenic patients. Children treated with
Soliris may be at increased risk of developing serious infections due to Streptococcus
pneumoniae
and Haemophilus influenza type b (Hib). Soliris
treatment of patients with PNH should not alter anticoagulant management
because the effect of withdrawal of anticoagulant therapy during Soliris
treatment has not been established. Administration of Soliris may result
in infusion reactions, including anaphylaxis or other hypersensitivity
reactions.



In patients with PNH, the most frequently reported adverse events
observed with Soliris treatment in clinical studies were headache,
nasopharyngitis, back pain and nausea. In patients with aHUS, the most
frequently reported adverse events observed with Soliris treatment in
clinical studies were headache, diarrhea, hypertension, upper
respiratory infection, abdominal pain, vomiting, nasopharyngitis,
anemia, cough, peripheral edema, nausea, urinary tract infections, and
pyrexia.



About Alexion



Alexion is a global biopharmaceutical company focused on developing and
delivering life-transforming therapies for patients with devastating and
rare disorders. Alexion is the global leader in complement inhibition
and has developed and commercializes the first and only approved
complement inhibitor to treat patients with paroxysmal nocturnal
hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two
life-threatening ultra-rare disorders. In addition, Alexion’s metabolic
franchise includes two highly innovative enzyme replacement therapies
for patients with life-threatening and ultra-rare disorders,
hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).
Alexion is advancing its rare disease pipeline with highly innovative
product candidates in multiple therapeutic areas. This press release and
further information about Alexion can be found at: www.alexion.com.



[ALXN-G]



Forward-Looking Statement



This news release contains forward-looking statements, including
statements related to the potential medical benefits of Soliris®
(eculizumab) for the treatment of myasthenia gravis, and Alexion's
future clinical, regulatory and commercial plans for Soliris for the
treatment of myasthenia gravis. Forward-looking statements are subject
to factors that may cause Alexion's results and plans to differ from
those expected, including for example, decisions of regulatory
authorities regarding the adequacy of our research, marketing approval
or material limitations on the marketing of our products, delays,
interruptions or failures in the manufacture and supply of our products
and our product candidates, failure to satisfactorily address matters
raised by the FDA and other regulatory agencies, the possibility that
results of clinical trials are not predictive of safety and efficacy
results of our products in broader patient populations, the possibility
that current rates of adoption of Soliris in PNH, aHUS or other diseases
are not sustained, the possibility that clinical trials of our product
candidates could be delayed, the adequacy of our pharmacovigilance and
drug safety reporting processes, the risk that third party payors
(including governmental agencies) will not reimburse or continue to
reimburse for the use of our products at acceptable rates or at all,
risks regarding government investigations, including investigations of
Alexion by the SEC and DOJ, the risk that anticipated regulatory filings
are delayed, the risk that estimates regarding the number of patients
with PNH, aHUS, HPP and LAL-D are inaccurate, the risks of shifting
foreign exchange rates, and a variety of other risks set forth from time
to time in Alexion's filings with the U.S. Securities and Exchange
Commission, including but not limited to the risks discussed in
Alexion's Annual Report on Form 10-K for the period ended December 31,
2016 and in our other filings with the U.S. Securities and Exchange
Commission. Alexion does not intend to update any of these
forward-looking statements to reflect events or circumstances after the
date hereof, except when a duty arises under law.
































































References



 

 

1.

 

Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of
refractory myasthenia gravis patients. Yale J Biol Med. 2013;
86:255-60.



2.


Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup
classification and therapeutic strategies. Lancet Neurol.
2015;14:1023-36.



3.


Drachman D, Adams R, Hu R, Jones R, Brodsky R. Rebooting the immune
system with high-dose cyclophosphamide for treatment of refractory
myasthenia gravis. Ann NY Acad Sci. 2008;1132:305-314.



4.


Sathasivam S. Diagnosis and management of myasthenia gravis. Prog
Neurol Psychiatry. 2014;18(1):6-14.



5.


Howard JF, ed. Myasthenia Gravis: A Manual for the Health Care
Provider. St. Paul, MN: Myasthenia Gravis Foundation of America,
Inc.; 2008.



6.


Safety and efficacy of eculizumab in refractory generalized
myasthenia gravis (REGAIN study). Clinicaltrials.gov identifier
NCT01997229.



7.


Melzer N, Ruck T, Fuhr P, et al. Clinical features, pathogenesis,
and treatment of myasthenia gravis: a supplement to the Guidelines
of the German Neurological Society. J Neurol. 2016 Feb 17. [Epub
ahead of print]



8.


Targeting the Complement System in Refractory Myasthenia Gravis.
Supplement to Neurology Reviews. February 2016.



Contacts


Alexion Pharmaceuticals, Inc.
Media
Arne Naeveke, PhD,
475-230-3774
Executive Director, Product Communications
or
Investors
Elena
Ridloff, CFA, 475-230-3601
Vice President, Investor Relations

Global Smartphone 3D Camera Market (2016-2022) - By Technol… 2017年03月23日 04時19分

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global
Smartphone 3D Camera Market (2016-2022)"
report to their
offering.




The recent technological advancements have driven the adoption of
cameras in smartphones. Initially, 3D cameras were standalone options;
however, with breakthroughs in technology and innovative sizes, 3D
cameras are now installed within a smartphone.



3D camera technology nevertheless requires advanced hardware support in
smartphones, namely better storage space and advanced processors.
Increasing adoption of smartphones and rapid technological advancements
has led to the growth of the global smartphone 3D camera market. Several
companies are heavily investing in research and development activities
to launch advanced and innovative smartphone 3D cameras. Extensive R&D
activities by different organizations would substantially contribute to
the growth of the smartphone 3D camera market, globally.



Based on the technology, the Smartphone 3D Camera market is segmented
into Stereoscopic Camera and Time of Flight. Based on Resolution Type,
the market is segmented into Below 8MP, 8MP to 16 MP and Above 16 MP.
Based on region, the Smartphone 3D Camera market is segmented into North
America (US, Canada, Mexico and Rest of North America), Europe (Germany,
UK, France, Russia, Spain, Italy and Rest of Europe), Asia-Pacific
(China, Japan, India, Taiwan, South Korea, Singapore and Rest of
Asia-Pacific) and Latin America, and Middle East & Africa. Asia-Pacific
remained the dominant region in the global Smartphone 3D Camera market
in 2015. North America and Europe would witness promising CAGR during
the forecast period (2016-2022).



Companies Mentioned




  • Toshiba Corporation


  • NXP Semiconductors N.V.


  • Texas Instruments Incorporated


  • Samsung Electronics Co. Ltd.


  • Sony Corporation


  • Panasonic Corporation


  • Microsoft Corporation


  • Intel Corporation


  • Infineon Technologies AG



Key Topics Covered:



1. Market Scope & Methodology



2. Executive Summary



3. Market Overview



4. Global Smartphone 3D Camera Market by Technology



5. Global Smartphone 3D Camera Market by Resolution



6. Global Smartphone 3D Camera Market by Region



7. Company Profile



For more information about this report visit http://www.researchandmarkets.com/research/gr7m9c/global_smartphone.


Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Smartphones
and Mobile Devices

Ullink Launches MiFID II Trade Reporting Solution 2017年03月22日 23時00分


Multi-asset solution will enable firms to comply with post-trade
transparency rules set to come into force in 2018




LONDON--(BUSINESS WIRE)--Ullink, a global provider of electronic trading and connectivity
solutions to the financial community, has launched its MiFID II
compliant trade reporting solution to help its clients meet regulatory
requirements for greater accuracy in reporting and timeliness of data
collection.



Trade reporting reform is a core component of MiFID II. Under the new
rules, details of all trades in eligible financial instruments (both
equity and non-equity) need to be published to market participants in as
close to real time as possible. In practice, for some instruments this
means no later than 1 minute after the trade.



This move is posing significant challenges for market participants,
illustrated in a recent survey conducted by WBR Research. The survey,
which polled 150 equity traders in Europe, found 37% of respondents
cited ‘post-trading issues’ as the factor expected to cause the biggest
impact of MiFID II reforms.



With more than 15 years’ experience delivering trading solutions to
capital markets firms, Ullink has fast-tracked the analysis of ESMA
specifications to build an automated solution that will handle
cross-asset class trade reporting requirements. The solution provides a
central dashboard, providing status of reporting and ability to amend /
cancel reports across multiple trade reporting venues operating under
Approved Publication Arrangements (APAs). The solution includes Smart
Report Routing logic for selecting amongst APAs based on business rules
to optimise trade reporting costs.



Richard Bentley, Chief Product Officer at Ullink comments: “With MiFID
II implementation drawing closer, there is increasing pressure on firms
to deploy automated solutions for trade reporting that can apply the
rules correctly, to eliminate possibility of over- or under-reporting.
The changing APA landscape also focuses attention on centralised
solutions which can process input from multiple front-office Order
Management Systems, across asset classes. The new Ullink Trade Reporting
solution is a powerful addition to Ullink’s portfolio, aimed at
alleviating the burden of new regulations for post-trade workflows.”



-Ends-




Contacts


ULLINK
Mireille Adebiyi
Marketing & Communications
Director
Tel.: +33 1 49 95 30 00
mireille.adebiyi@ullink.com
www.ullink.com
or
COGNITO
Tel:
+44 (0)20 74269420
Oliver Mann
Oliver.Mann@cognitomedia.com
or
Paul
Bowhay
Paul.Bowhay@cognitomedia.com



Traditional Techniques Re-Envisioned with Modern Design The… 2017年03月22日 22時00分

FUKUSHIMA, Japan--(BUSINESS WIRE)--Fukushima Prefecture:








Sharing the Intense Technical Skills and Historical Beauty of
Fukushima’s Handicrafts



Fukushima Prefecture is home to many traditional handicrafts,
woodworking techniques, and folk crafts, passed down from generation to
generation, including traditional Aizu lacquerware, Aizu woven cloth,
and Miharu Hariko (traditional dolls created with a papier-maché
technique).



These traditional handicrafts that Fukushima Prefecture is rightly proud
of are being reborn with new designs to share the beauty of Fukushima.
This effort involves collaborations with several creative professionals,
first and foremost is the world-famous designer, Junko Koshino, who is
working with a total of eleven companies. Other professionals are
involved with an additional four companies.



Melding Traditional Techniques and Creativity in Ways That Suit
Modern Lifestyles



These products, created by the different creative professionals, not
only take advantage of techniques fostered and refined by Fukushima
artisans, but also reflect designs that easily accompany our modern
lifestyles.



Junko Koshino focused on products related to food and the ways we eat,
creating dishes, placemats, and candles, among other beautiful items, to
coordinate well with the things around our tables. Sales are set to
begin this spring.



Take note of Fukushima’s newest challenge, arising from a fusion of the
intense techniques that underlie our traditional crafts with
world-renowned creativity.



More information on the collaborative products can be found online at http://fukushima-cp.com.




Contacts


Kindly direct inquiries to:
Fukushima Prefectural Government
Takashi
Tsurumaki, +81-24-521-7124
Assistant Chief, Public Relations Section
General
Affairs Division
FAX: +81-24-521-7901
2-16 Sugitsuma-cho,
Fukushima City, 960-8670 Japan



Mitsubishi Electric Announces Dividend Policy for Fiscal 20… 2017年03月22日 15時20分

TOKYO--(BUSINESS WIRE)--Mitsubishi
Electric Corporation
(TOKYO:6503) announced today its dividend
forecast for the current fiscal year ending March 31, 2017 (fiscal 2017).




The company plans to pay a year-end dividend of 18 yen per share, as of
the record date of March 31, 2017, with due consideration of performance
and financial standing in fiscal 2017. The actual dividend will be
declared at the Board of Directors’ meeting when financial results for
fiscal 2017 are to be approved.











































 

Dividend per share

 

Interim dividend

 

Year-end dividend

 

Annual dividend


Fiscal 2017
(previous announcement as of Feb. 2, 2017)




9 yen (actual)


To be determined


To be determined

Fiscal 2017 (present announcement)


9 yen (actual)


18 yen


27 yen

Fiscal 2016 (actual)

 

9 yen

 

18 yen

 

27 yen














 


Note:



 


The forecast above is based on assumptions deemed reasonable by
the company at the present time, and actual results may differ
significantly from forecasts.



 


For the full text, please visit: http://www.mitsubishielectric.com/news




Contacts


Mitsubishi Electric Corporation
Investor Relations Inquiries
Investor
Relations Group, Corporate Finance Division
Tel: +81-3-3218-2391
Cad.Irg@rk.MitsubishiElectric.co.jp
or
Media
Inquiries

Arisa Mori, +81-3-3218-2810
Public Relations
Division
prd.gnews@nk.MitsubishiElectric.co.jp
www.MitsubishiElectric.com/news/



Niseko Classic Showing International Appeal 2017年03月22日 13時00分

NISEKO, Japan--(BUSINESS WIRE)--The fourth annual Niseko Classic, Japan's only UCI Gran Fondo World
Series qualifier, is scheduled for July 9, 2017 in Niseko, Hokkaido,
Japan. Race participants will ride on fully closed roads and experience
some of the most breathtakingly scenic cycling in Japan, taking them
over mountain passes, through farmland and along the ocean. Over 1000
athletes from 25 countries including Japan, Singapore, Hong Kong,
Malaysia, Taiwan, Norway, Australia, USA, Italy, UK, Netherlands are
registered for the race. Niseko Classic warmly welcomes riders of all
levels: those who aim to make the podium and others who wish to cross
the finish line in the best possible time.




Riders have the choice between the 140km long course, with a challenging
2,362m of climbing including ascents of the Niseko Panorama Line and
famous Nimi Onsen climbs. The single-loop course will take riders
through Hanazono, over the mountain ranges into the farming district of
Kyowa town, and follow the Shiribeshi river to its mouth on the coast of
the Sea of Japan where they will turn back and traverse the other side
of the mountains into Niseko Valley and over rolling hills into Grand
Hirafu Resort.



A shorter, but equally testing 70km course starts in Rankoshi town and
follows the Shiribeshi across farming flatlands to the Sea of Japan. The
course returns on the opposite side of the river and ascends crossing
the ranges before coming down into the Niseko valley, and winding around
the base of Mt. Annupuri towards the finish in Niseko.



Both routes finish in the heart of the town of Grand Hirafu, an
international ski resort revered for its legendary powder snow. A local
food and beer festival awaits the riders, where they can sample famous
Niseko produce and Japanese delicacies. With the entire community
supporting the event, it’s a fantastic fun-filled weekend for
non-cyclists too, with performances, music, traditional displays and
fireworks.



For the age groupers in the peloton, the Niseko Classic serves as an
official qualifier for the UCI Gran Fondo World Championships in Albi,
France on August 24th, 2017. The top 25% in each age group earn one of
the coveted spots where they will compete against the world’s best.



Entries open now!



For Niseko Classic race and event details please see http://bit.ly/nisekoclassic2017




Contacts


Hokkaido Events
Kento Maeda, +81-136-55-6081
kento@hokkaidoevents.com



Sumitomo Electric Renews World Record of Lowest Loss Optica… 2017年03月22日 09時00分

OSAKA, Japan--(BUSINESS WIRE)--Sumitomo Electric Industries, Ltd.  (TOKYO:5802) (ISIN:JP3407400005)
has set a new world record for the lowest loss of optical fiber, 0.1419
dB/km.






As the demand for communication capacity is skyrocketing over the world,
there have been increasing needs for improvement in the performance of
optical communication systems. For such improvement, reduction in
optical fiber’s transmission loss is an effective solution. Since the
commercialization of ultra-low loss fiber*1 in 1988, Sumitomo
Electric has been pioneering the cutting-edge technologies including
transmission loss reduction. With these technologies, the Company has
been supplying ultra-low loss fibers that have the lowest transmission
losses among the commercial products.





Now Sumitomo Electric has advanced the technology of fiber-glass and
polymer coating and successfully reduced the transmission loss further
down to 0.1419 dB/km at a wavelength of 1560 nm, setting a new world
record for the lowest loss of optical fiber. We will continuously
develop the technologies for offering the very best products, and
contribute to expansion of communication capacity especially in
trans-oceanic submarine communication systems.



This work has been accepted as a post-deadline paper*2 at
Optical Fiber Communication Conference (OFC) 2017 held in Los Angeles,
and will be presented on March 23, 2017.



Reference
• Press release on March 27, 2013
Sumitomo Electric
has set a New World Record of the Lowest Optical Transmission Loss and
Starts Shipment of Optical Fibers with Low Transmission Loss and Large
Effective Core Area Fibers
http://global-sei.com/news/press/13/prs032_s.html



*1 Ultra-low loss fiber
Optical fiber whose core is composed of
pure silica (SiO2) and has extremely low transmission loss.
Most typically, Sumitomo Electric’s Z-PLUS Fiber™ ULL and Z-PLUS Fiber™
130 ULL have transmission losses as low as 0.152 dB/km at a wavelength
of 1550 nm, which are the lowest among the commercial products.



*2 Post-deadline paper
Paper that is regarded as important
cutting-edge research work and accepted after the deadline for regular
papers.




Contacts


Sumitomo Electric Industries, Ltd.
Takashi Shiraga / Kanako Fujima,
+81-6-6220-4119
Public Relations Dept.
http://global-sei.com/

ANK免疫細胞療法の治療経過を学会発表 2017年03月22日 09時00分


リンパ球バンクがANK免疫細胞療法のための培養センターを提供


東京--(BUSINESS WIRE)--(ビジネスワイヤ) --
先進的ながん免疫細胞療法をサポートするリンパ球バンク株式会社(本社:東京都千代田区、代表取締役:藤井真則)が運営する細胞培養センターを利用し、ANK免疫細胞療法を提供する医師が、細胞培養を実施する医師らと共同で、3月7日から10日に東京で開催された、「第18回
国際ヒトレトロウィルスHTLV会議」で、ANK免疫細胞療法の治療経過を発表しました。








発表内容は、標準治療が確立していない難治性のATL成人T細胞白血病の患者9名に対して、ANK免疫細胞療法を用いたところ、症状の改善が見られ、長期生存例が得られている、というものです。



「第18回 国際ヒトレトロウィルスHTLV会議」での発表内容



今回、「第18回
国際ヒトレトロウィルスHTLV会議」で発表したのは、ATL患者が多い南九州で、臨床にあたる医師と、京都にあるリンパ球バンク株式会社の細胞培養センターを利用して、細胞培養の受託業務を行う医師ら3名。



内容は、ATL成人T細胞白血病9症例についての経過です。9症例のうち、4名は治療により症状改善後、3~7年が経過しご存命、1名は治療後6年間、再発もなく経過した後、ATLとは関係のない疾病で亡くなられ、4名はATLの急性化を止めきれなかったケースや、他の疾病等が原因で、治療途上で亡くなられています。



ATL成人T細胞白血病とは



ATL成人T細胞白血病は、HTLV-1型ウイルスの感染者のうち、生涯で数%が発症します。抗がん剤が奏効しにくく、奏効した場合も直ちに再燃し、抗がん剤投与後の平均余命は13ヶ月に過ぎません。骨髄移植が行われることもありますが、副作用が激しいため高齢者は治療できず、一方、患者の多くが高齢者です。標準治療が確立しているとは言えない難治性の高い疾病です。現状では、重篤なレベルに症状が進行するまで、補助的な治療以外は行われないのが一般的です。その点、一過性の発熱等はあるものの、強い副作用(副反応)が見られず、体力的に高齢者でも治療可能なANK免疫細胞療法が、もしATLの治療に有効であれば、患者さんや、ウイルスキャリアの方々にとって、朗報となります。



患者からの要請を受けて学会発表



ATL患者のお一人に、急性転化の兆しが現われ(添付図参照:腫瘍マーカーの推移)、ANK免疫細胞療法を通常の1クールの3分の2のみ実施したところ、症状が消失し、6年間、他の治療も受けずに、再発もなく、お元気に過ごされ、ATLとは関係のない他の疾病で亡くなられました。口コミ等で、患者さんが集まりましたが、これまでの治療経過をまとめて、学会などで発表して欲しいという患者さんや、ご家族の方々からの要請もあり、最初の患者さんを治療した南九州の医師が中心に、今回の発表となりました。



免疫細胞療法で白血病は治療できないと言われている理由



一般的に、免疫細胞療法では白血病を治療できないと言われています。理由は、白血病の場合、培養に用いられる細胞を血液から採取した時点でがん細胞が混入しますが、培養中に増殖した混入がん細胞を患者さんに戻すことに問題があるためです。研究目的で、混入がん細胞を洗浄除去した後に、免疫細胞を培養するケースはありますが、前処理を行わず、臨床上の実用レベルで、白血病を治療できる免疫細胞療法は見当たりません。



ANK免疫細胞療法の場合も、混入がん細胞があまりに多いと培養は無理ですが、あるレベル以下であれば、培養中にATL細胞を全滅させることも可能です。



ANK免疫細胞療法



患者さんご自身の血液を5~8リットル(延べ数量)、成分採血等に用いる装置で体外循環させ、血液に含まれるリンパ球を選別して、採りだします。その中のNK細胞を高度に活性化し、選択的に増殖させる技術。高度に活性化されたNK細胞は、がん細胞を傷害する爆弾のような小胞体を細胞内に大量に抱えるため、細胞分裂の際に爆弾が破裂し、自爆しやすい傾向があります。そのため、臨床上の実用として意味のあるレベルの活性化と増殖の両立は難しいとされてきましたが、京都大学の研究者2名がこの難題をクリアし、活性と増殖、両方の意味を込めて増強された=Amplified
NK(ANK)と名付けました。この治療で進行がんを克服した患者と、研究者らが、2001年にリンパ球バンク株式会社を創業しました。



治療では、培養されたANK細胞を、点滴で体内に戻します。がん細胞を攻撃するのが本職のNK細胞の機能をそのままに、直接、がん細胞を傷害する上、大量の免疫刺激物質を放出することで、体内のNK細胞の活性化も促します。この時、放出される免疫刺激物質は、ほとんどが発熱を誘導する性質をもつため、点滴後、一過性ですが、悪寒や高熱などの副反応がでます。



免疫細胞療法の背景と特徴



強力な免疫刺激により、がんが消失することがある、あるいは、免疫抑制剤の大量投与により、がんが異常増殖する、といった様々な現象から、私たちの体内には、がん細胞を強力に傷害する免疫細胞が存在すると考えられてきました。1970年代、T細胞や樹状細胞、マクロファージ等は、既に知られていましたが、がん細胞への反応はそれ程でもなく、もっと強い細胞の探索が精力的に行われた結果、活性が高ければ、どのようながん細胞でも、出会ったその場で直ちに攻撃するリンパ球がみつかり、ナチュラルキラー(NK)細胞と名付けられました。がん細胞を認識する専用センサーを多種大量に備え、攻撃力も圧倒的に強く、体内の存在数も1000億個レベルと、非常に多いという腫瘍免疫の主役が発見されたのです。今日では、がん患者体内の、NK細胞は活性が低下しており、がん細胞の増殖を許してしまっていることが知られています。



米国国立衛生研究所(NIH)では、数十リットルという大量の血液からNK細胞を体外に採り出し、強く刺激してから3日以内に培養期間を制限し、患者体内に戻す免疫細胞療法の大規模臨床試験を実施、抗がん剤が奏効しないがん患者数百名全員に何らかの効果を示しました。3日以上培養すると、増殖に伴って、活性の高いNK細胞が自爆を起こしやすくなりますが、短期間の間に、大量の活性化されたNK細胞を体内に戻すと、大きな腫瘍が壊死を起こし、腫瘍内部のカリウム等が大量に放出され、心停止などのリスクがありました。そのため、治療はICUを占拠し、体液コントロールを行いながら実施され、非現実的なコストがかかり、実用化は無理でした。



NK細胞は培養が非常に難しく、活性を高めないと役に立ちませんが、増殖が始まると強い攻撃力ゆえに自爆を起こし易いという問題があります。京都大学の研究者二人が、米国法の限界を超えて、NK細胞の活性化と増殖を同時に実現するANK自己リンパ球免疫療法(ANK免疫細胞療法)を開発し、小規模な臨床試験を経て、一般診療を始めました。ANK免疫細胞療法1クールは、NK活性においても、NK細胞数においても、NIH法を上回るため、一度に体内に戻すと大きな腫瘍が壊死を起こすリスクがあります。そこで、培養細胞は凍結保管され、1クールを12回に分け、融解・再培養を行いながら、原則、週2回ずつに分割投与することで、クリニックへの通院治療が可能な安全性を確保しました。



ANK免疫細胞療法は、強い免疫刺激の結果として、国内で唯一、40度前後の発熱を伴います。



標準治療では、がん細胞が飛び散ってしまうと一般に予後不良です。体内に分散するがん細胞を追いかけ、一つずつ仕留めるNK細胞をがん治療に活用することは、進行がんの治療において重要な鍵を握ると考えられています。













































 

【 リンパ球バンク株式会社の概要 】

○本社

 



 

東京都千代田区紀尾井町3-32 紀尾井町WITHビル 3F

○代表者






代表取締役会長 勅使河原 計介、代表取締役社長 藤井 真則



○資本金





8550万円

○設立





2001年1月 京都大学発ベンチャーとして設立

○事業内容

 



 

ANK自己リンパ球免疫療法総合支援サービス
























 

○企業理念

リンパ球バンク株式会社は、ANK免疫細胞療法を開発した医師と治療を受けた患者を中心に創業され、経営している企業です。

一人でも多くのがん患者にとって治療の選択肢が広がる状況を築いていきます。

科学的根拠に基づいたオーソドックスな考え方で治療システムを開発・提案します。

高度で複雑な生命システムを謙虚にみつめ、細胞加工技術や免疫制御技術を過信せず、細胞本来がもつ能力をありのまま引き出すことを工夫します。

がんの予防や治療における免疫の重要性への認知を広めることで、免疫細胞療法が社会システムに組み込まれ、より多くの患者が治療を受けられる機会を広げます。



Contacts


【本件に関するお問い合わせ先】
リンパ球バンク株式会社
担当:斎野千栄子
TEL 0120-51-2251
〒102-0094
東京都千代田区紀尾井町3-32
e-mai : ly-seminar@lymphocyte-bank.co.jp
https://www.lymphocyte-bank.co.jp/

D23 Expo Disney Fan Event to Be Held in Japan in 2018 2017年03月22日 09時00分

MINATO-KU, Tokyo--(BUSINESS WIRE)--The Walt Disney Company (Japan) announced today that it will stage D23
Expo Japan 2018, a special event for Disney fans created by D23: The
Official Disney Fan Club, over three days from February 10 to February
12, 2018, at Tokyo Disney Resort in Maihama.




D23 Expo is held every two years in the U.S. for Disney’s most
passionate fans. The first D23 Expo in Japan was held in 2013 and is
unique to Japan while remaining true to the original vision of “The
Ultimate Disney Fan Event.” D23 Expo Japan 2015 was themed to “The Power
of Story.” Guests were treated to spellbinding stories from each of the
four Disney brands—Disney, Disney•Pixar, Star Wars, and Marvel.
Fans enjoyed experiences, merchandise, collectibles, and endless
surprises created exclusively for the event.



D23 Expo Japan 2018 will once again feature special exhibits and
opportunities for the delight and enjoyment of guests. Further details
will be posted at http://disney.jp/D23
as they become available this summer.



“We heard from a lot of fans about how delighted they were with the D23
Expo Japan 2013 and 2015.D23 Expo Japan 2018 promises to be even more
spectacular,” said Paul Candland, President, Walt Disney Asia
and President, The Walt Disney Company (Japan) Ltd. “2018 marks The Walt
Disney Company’s 95th anniversary and the 90th anniversary of Mickey
Mouse’s screen debut. In Japan, it marks Tokyo Disney Resort’s 35th,
Disney Channel’s 15th, and the Disney★JCB Card’s 10th. We’re very
excited about being able to present this great event once again, and we
know our guests will have an incredible experience during the three days
we have planned for them.”



About Walt Disney Japan



The Walt Disney Company marked its formal move into the Japanese market
by establishing a local subsidiary in 1959. In April 2000, several
Japanese affiliates were integrated to form a new company, The Walt
Disney Company (Japan) Ltd., to oversee all Disney interests in Japan.
Walt Disney Japan runs a diversified business building on synergies
created by the following segments—Studio Motion Pictures, Television,
Consumer Products & Interactive, Media Distribution, Disney Store Japan
and Parks & Resorts.



About D23: The Official Disney Fan Club



The name D23 pays homage to the exciting journey that began in 1923 when
Walt Disney opened his first studio in Hollywood. D23 is the first
official fan club in Disney’s 90-plus-year history. It gives its members
a greater connection to the magical world of Disney through its
quarterly magazine Disney twenty-three, information-packed
website D23.com, member-exclusive discounts, and special events like the
D23 Expo held in Anaheim, California.



About D23 Expo in the U.S.



D23 Expo: The Ultimate Disney Fan Event has been held in the U.S. four
times to date, drawing Disney fans from around the world to Anaheim,
California. D23 Expo 2017 will take place at the Anaheim Convention
Center the weekend of July 14–16. Highlights include what’s new and
what’s on the horizon from theme parks, television, music, gaming, and
films, including Pixar, Star Wars, and Marvel; the Disney Legends
Ceremony to honor the talented men and women who have made significant
contributions to the Disney legacy; an all-new exhibit curated by the
Walt Disney Archives; the D23 Expo Emporium, where Disney fans can buy,
sell, and trade Disney collectibles, memorabilia, merchandise, and more;
and D23 Expo’s costume contest.




Contacts


The Walt Disney Company (Japan)
Sayo Inomata
Sayo.Inomata@disney.com
or
The
Walt Disney Company
D23: The Official Disney Fan Club
Jeffrey
Epstein
Jeffrey.R.Epstein@Disney.com

Village Island Releases World-Wide the VICO-4, the “4K over… 2017年03月22日 00時23分

TOKYO--(BUSINESS WIRE)--Village Island, a video equipment supplier and integrator head-quartered
in Japan, announces VICO-4 from the VICO
series enabling UHD smart transport and powered by TICO, the
revolutionary high-efficiency compression engine from intoPIX.



Using the new VICO-4 appliance, it is now possible to transport 4K
base-band video over a single 3G-SDI, without losing any noticeable
video quality and with zero-frame delay. VICO-4 takes in 4K as 4x 3G-SDI
or 1x 12G-SDI and convert it into a single 3G-SDI. The unit can easily
switch between Encoder and Decoder.



VICO is powered by TICO, the high-efficiency compression engine from
intoPIX enabling 4:1 Visually Lossless compression with a total delay
(encoder plus decoder) of only a few video lines (less than 1ms).



Why VICO?




  • As broadcasters move towards 4K, they desire to make a smart use of
    their current SDI facilities. The resulting 3G-SDI codestream signal
    can be interfaced with 3G-SDI uncompressed traditional devices such as
    Distribution Amplifiers, Storage/Playout system, Optical Transmitters,
    Matrix-Switchers and Routers,...


  • Because broadcasters operators have preference to ideally transport
    video as raw data (or equivalent to raw quality) and with near-to-zero
    delay.


  • To respond to the needs for SDI practical connection when IP is not an
    option or when the existing IP network is bringing inadequate
    constraints or complexity.


  • To offer a mission critical hardware that is simple to configure
    without requiring additional peripherals or software.


  • To offer ready-to-integrate appliance for OBVAN, studios and
    contribution system.


  • To resolve 4K-SDI cabling issues related to limitation of space and of
    distance between devices.



VICO handles 4K video as 4x 3G-SDI in both 2SI (2-Sample-Interleave) and
SQD (Square-Division) modes, in Level A and B. It also supports 12G-SDI
which makes it a unique gateway for new 12G-SDI devices.



SDI transport of TICO video data is done according to SMPTE RDD35 SDI
specifications to enable interoperability with third-party vendors.
Several interoperability testing have been conducted successfully.
According to this spec, the resulting 3G-SDI codestream sees the SDI
video active area replaced with the 4K compressed data. The complete
ancillary data (ex: audio, time-codes, sub-titles, …) is transported as
is.



TICO compression enables to preserve the original quality without any
artefact detectable by the human eye. Encoding and decoding is achieved
within a few video lines delay. Therefore VICO enables 4K transport over
single 3G-SDI with lossless quality coupled with Ultra-Low Delay. VICO
is available as OEM and ODM as well.



About Village Island
Village
Island
, with headquarters in Japan and subsidiary offices in
Singapore and Malaysia, is a well-known supplier of audio-visual
hardware and solutions for the broadcast industry. Village Island is an
IABM member and a TICO
Alliance
member.



About intoPIX
intoPIX
is an innovative provider of compression technology to audiovisual
equipment manufacturers. It includes silicon IP-cores and software tools
that enable leading-edge TICO and JPEG2000 compression, video over IP
and hardware enforcement.




Contacts


intoPIX
Raiffa Lanove, +3210238470
press@intopix.com



The New Vanta Handheld X-ray Fluorescence (XRF) Analyzer fo… 2017年03月21日 22時00分

WALTHAM, Mass.--(BUSINESS WIRE)--#Axon--Olympus’ latest addition to the Vanta™ series of handheld XRF
analyzers is optimized to help ensure compliance with the Restriction of
Hazardous Substances Directive (RoHS) and local or international
regulatory laws. Like every Vanta analyzer, this new model combines
fast, accurate results with a durable design for maximum uptime and a
lower cost of ownership.








Vanta analyzers provide on-the-spot chemical analysis to quickly scan
for toxic metals like lead (Pb), cadmium (Cd), mercury (Hg), chromium
(Cr) and bromine (Br) in consumer products such as toys, apparel,
footwear and electronics to comply with RoHS regulations. Excellent
sensitivity and repeatability enable Vanta analyzers to achieve low
detection limits for reliable pass/fail results of regulated elements.



Vanta XRF analyzers are accepted as a screening tool when testing for
compliance with the following global hazardous substance regulations and
testing methods as part of a reasonable testing program:




  • EU RoHS Directive (2011/65/EU)


  • China RoHS Directive (RPCEP)


  • Japan RoHS


  • Korean RoHS Directive


  • USA CPSIA (HR4040)


  • USA Halogen Free Directive


  • California Preposition 65


  • USA CPSC-CH-E1002-08 SOP



Vanta analyzers are IP65 rated* for protection against dust and water
and drop tested to military standards (MIL-STD-810 G) for greater
uptime. Vanta analyzers also incorporate Olympus’ revolutionary new
Axon™ technology, a breakthrough in XRF signal processing that utilizes
ultra-low-noise electronics to deliver higher X-ray count rates per
second and test-to-test repeatability. The analyzer’s lower limits of
detection accommodate future compliance as regulations change over time.
Other features include:




  • Intuitive interface and responsive touch screen


  • Optional Wi-Fi and Bluetooth® connectivity for fast data
    downloads


  • Customizable home screen



Olympus’ newest Vanta analyzer combines durability, power and ease of
use for testing consumer goods.



About Olympus



Olympus Corporation operates in industrial, medical, and consumer
markets, specializing in optics, electronics, and precision engineering.
Olympus is a world-leading manufacturer of innovative test and
measurement solutions that are used in industrial and research
applications ranging from aerospace, power generation, petrochemical,
civil infrastructure, and automotive to consumer products.



For more information about Vanta handheld XRF analyzers and Olympus’
line of nondestructive testing products contact a sales representative
or visit http://www.olympus-ims.com.



*M series analyzers are IP64 rated.



Vanta and Axon are trademarks of Olympus Corporation.



The Bluetooth® word mark and logos are registered trademarks
owned by Bluetooth SIG, Inc. and any use of such marks by Olympus
Corporation is under license.




Contacts


Media Contact:
Olympus Corporation
Michelle Wright,
781-419-3664
Michelle.Wright@olympus-ossa.com

ハンドヘルド蛍光X線(XRF)分析計VANTAシリーズに新モデル登場。… 2017年03月21日 22時00分

米国マサチューセッツ州ウォルサム--(BUSINESS WIRE)--(ビジネスワイヤ)-- オリンパスのハンドヘルド蛍光X線分析計のVANTAシリーズに加わる新モデルは、RoHS規制およびさまざまな国・地域の法的規制への対応を確認できるよう、最適化されています。VANTAの既存モデルと同様に、新モデルは高速かつ高精度な測定結果の取得と堅牢設計を兼ね備えており、稼働時間を伸ばすことにより所有コストの低減に貢献します。








携帯型のVANTAによって、検査の現場で分析を行うことができ、電気・電子機器や、玩具、衣類などの生活・家庭用品に含有される鉛(Pb)、カドミウム(Cd)、水銀(Hg)、クロム(Cr)、臭素(Br)などの有害金属を迅速に検出し、RoHS規制への対応が確認できます。※クロム、臭素は総量で測定。VANTAは優れた感度と再現性で低い検出限界を実現し、規制元素の高精度なスクリーニング判定が可能です。



VANTAは、有害物質に関する以下のグローバルな規制/指令および検査規格についての対応を確認するスクリーニングツールとして有効な分析計です。




  • EU RoHS指令(2011/65/EU)


  • 中国RoHS


  • 資源有効利用促進法(J-Moss)


  • 韓国RoHS


  • USA CPSIA(HR4040)


  • USAハロゲンフリー規格


  • California Preposition 65(安全飲料水および有害物質施行法)


  • USA CPSC-CH-E1002-08 SOP



VANTAは、IP65に準拠した*防塵防水性能規格と、米国軍用規格(MIL-STD-810
G)の落下試験で求められる耐久性を備えています。またVANTAには、オリンパス独自の新技術AXON
TECHNOLOGYの画期的なXRF信号処理方法が採用されています。この技術では低ノイズの電子素子を用いているため、1秒あたりのX線カウントレートが高く、優れたデータの再現性を実現します。検出限界が低く、今後もさまざまな法規制への対応確認用として使用可能と考えられます。その他の特長は以下のとおりです。




  • 使いやすい操作性と感度の良いタッチスクリーン


  • 高速データダウンロードが可能な、オプションの無線LANおよびBluetooth®に対応


  • カスタマイズ可能なホーム画面



VANTAシリーズの新モデルは、RoHS指令対応および一般消費財の検査に適した堅牢性、パワー、および操作性を兼ね備えています。



オリンパスの科学事業について



オリンパスの科学事業における主な製品は、光学顕微鏡、工業用内視鏡、および非破壊検査機器です。科学事業では、これらの製品を通して、医療・生命科学・産業分野における研究開発、生産現場における品質向上、航空機や自動車、大型プラントなどの検査による社会インフラの安心・安全確保に貢献しています。



ハンドヘルド蛍光X線(XRF)分析計VANTA、およびオリンパスの非破壊検査機器についての詳細は、お近くのオリンパスまたは当社のウェブサイトまでお問い合わせください。http://www.olympus-ims.com.



*Cシリーズ。MシリーズはIP64準拠。オプションのファン取り付け時はIP54準拠。



本リリースに掲載されている社名および製品名は各所有者の商標または登録商標です。



Bluetooth®ワードマークおよびロゴは、Bluetooth SIG,
Inc.が所有する登録商標であり、オリンパス株式会社はこれら商標を使用する許可を受けています。




Contacts


広報担当:
Michelle Wright, 781-419-3664
Michelle.Wright@olympus-ossa.com

New KYOCERA a-Si Photoreceptor Drum for Document Equipment … 2017年03月21日 21時07分


Core imaging component can print 1 million pages while reducing
internal component wear, extending equipment operating life


KYOTO, Japan--(BUSINESS WIRE)--Kyocera Corporation (NYSE:KYO)(TOKYO:6971) introduced a new imaging
component that is expected to set a new standard for durability in
office document equipment, including laser printers and multifunctional
products (MFPs) that use electrophotographic technology.








Kyocera’s new LF Series amorphous silicon (a-Si) photoreceptor drum
features a coefficient of friction 30 percent*1 lower than
that of the company’s conventional a-Si drum, while upholding the
conventional model’s status of offering the world’s longest operating
life (approximately 1 million printed pages without drum replacement)*2.
The new product is now available for shipment to equipment manufacturers
worldwide.




























 


Product Overview



Product name

 

LF Series a-Si photoreceptor drum

Size



Diameter: 30-40mm;
Length: 360mm



Production facility

 


Shiga Yohkaichi Plant (Japan)



 


In a key enhancement to the MS Series a-Si photoreceptor drum that
Kyocera launched in 2011, the new LF Series incorporates a proprietary
coating with submicron-scale variations in surface topography —
including microasperities measuring approximately 1×10-4 mm.
This unique surface treatment serves to reduce friction with peripheral
components that contact the drum by approximately 30 percent.
Consequently, by reducing internal friction, the new a-Si drum
contributes to extending the operating life of the printing equipment as
a total system, while retaining the world’s longest drum lifespan of
approximately 1 million pages.



Kyocera has promoted environment-friendly document equipment through its
long-life a-Si photoreceptor technology since 1984. The company hopes
that the longer equipment life made possible by its newly developed LF
Series print drum will reduce environmental impact even further.



Development Background



Many types of printers on the market today utilize disposable imaging
components. In contrast, since the launch of Kyocera’s first a-Si
photoreceptor drum in 1984, the company has used its proprietary
technology to continuously develop the photoreceptor drum into a durable
device with a lifespan equivalent to the mechanical life of the printer
itself.



Enhancing the lifespan of electrophotographic printing equipment
requires not only a more durable photoreceptor drum, but also more
long-lasting internal components. Reducing the friction of the
photoreceptor drum surface is therefore essential, since this surface
forms a contact interface with numerous other internal components that
are all subjected to increasingly faster print speeds.



Kyocera developed the world’s first*3 a-Si photoreceptor drum
with submicron-sized asperities by combining its proprietary thin-film
forming expertise utilizing DC electricity with its surface-processing
technology.



*1) Compared to Kyocera’s conventional a-Si drum with similar functions.
*2)
World’s longest operating life among conventional a-Si drums with
similar functions, based on research by Kyocera as of January 18, 2017.
*3)
World’s first a-Si photoreceptor drum with submicron-sized asperities
for electrophotographic printing, based on research by Kyocera as of
January 18, 2017.



For more info and images, please visit:
http://global.kyocera.com/news/2017/0308_mblf.html



About
KYOCERA



Kyocera
Corporation
(NYSE:KYO)(TOKYO:6971) (http://global.kyocera.com/),
the parent and global headquarters of the Kyocera Group, was founded in
1959 as a producer of fine
ceramics
(also known as “advanced ceramics”). By combining these
engineered materials with metals and integrating them with other
technologies, Kyocera has become a leading supplier of electronic
components, printers, copiers, solar power generating systems, mobile
phones, semiconductor packages, cutting tools and industrial ceramics.
During the year ended March 31, 2016, the company’s net sales totaled
1.48 trillion yen (approx. USD13.1 billion). Kyocera appears on the
Clarivate Analytics list of the “Top 100 Global Innovators” and is
ranked #531 on Forbes magazine’s 2016 “Global 2000” listing of the
world’s largest publicly traded companies.




Contacts


KYOCERA Corporation (Japan)
Natsuki Doi, +81-(0)75-604-3416
Corporate
Communications
webmaster.pressgl@kyocera.jp
Fax:
+81-(0)75-604-3516



Announcement of the Criteria for Certifying the New Mino-Wa… 2017年03月21日 18時59分


Introducing Mino-Washi, a paper with 1300 years of history and yet new
possibilities, to the world


GIFU, Japan--(BUSINESS WIRE)--On Tuesday March 21st, the new criteria for selecting high
quality Mino-Washi
and the logos of three new brands were introduced at the World premiere
Mino Washi (Japanese Paper) Brand Exhibit. Mino washi is a Japanese
paper with a history of 1300 years. Made in the city of Mino in Gifu
Prefecture, its production technique has been designated as a Cultural
Heritage by UNESCO in 2014.








The exhibit, organized by the Minowashi Brand Value Improvement Research
Group, consisting of the Gifu Prefectural Government, Mino City, and the
Minowashi Brand Cooperative Society, is being held in five cities around
the world: Tokyo, Gifu, New York, Paris and Milan. On display are new
and existing products using Mino-Washi made by artists and designers
from various fields, including art, architecture and product design.
These products suggest different techniques and new ideas for
Mino-Washi. The Mino-Washi Brand Book, which tells the story of
Mino-Washi, are distributed on site, and through both the products and
the brand book, the exhibit brings new opportunities for Mino-Washi to
be used as a new material.



The new brand logos



A set of new and strict criteria were established for Mino-Washi, and
only those products that meet the criteria can be allowed to use the
logos of the new brands. The three new brands are “hon-minoshi Japan”,
“mino-tesukiwashi Japan” and “mino-kikaisukiwashi Japan”. The criteria
needed to be reached in order to be certified into these brands are the
production site, manufacturer, materials, quality, relation to the
environment, and the base paper used. Although the criteria is strict,
products with these logos will be marked as high quality Mino-Washi, and
will surely be recognized as a brand that can be appreciated throughout
the world.



The Mino-Washi Brand Book



Mino washi paper, having a history of 1300 years, was born in the
bountiful nature of the Mino region and has been created using the clear
waters of the Nagara and Itadori rivers of the region. It has a soft and
delicate texture, and yet it is strong and durable due to the use of
both vertical and horizontal rocking techniques during production. This
production technique also leads to its smoothness, and these are all
aspects that makes Mino washi paper truly appealing.



Not only can you learn about the three new brands of Mino-Washi through
the brand book, but you can also learn about the production techniques
and the meanings behind each logo, and even touch and feel the papers
yourself.



You can download the brand book from the link. minowashi-japan.com




Contacts


Made in Japan Inc.
7-1-19-1501 Roppongi Minatoku, Tokyo 1060031
+81
35413 3243
Global@madeinjapan.jp



X-Chemが複数の治療領域でアステラス製薬との戦略的連携を発表 2017年03月21日 17時10分

米マサチューセッツ州ウォルサム--(BUSINESS WIRE)--(ビジネスワイヤ) -- 革新的な創薬能力を新規低分子医薬品の創出に適用している非上場バイオテクノロジー企業のX-Chem,
Inc.(X-Chem)は、アステラス製薬(アステラス)との広範な創薬連携契約の締結を発表しました。この連携により、1200億種以上の化合物を含むX-ChemのDNAエンコード化DEXTMライブラリーの拡大を続けるコレクションから、アステラスが関心を持つ複雑な創薬標的に対する新規リード化合物を発見することが可能になります。この新しい提携関係は、X-Chemが製薬会社と結ぶ初回の提携契約としては最も包括的なもので、アステラスの複数の治療領域において、創薬が困難な標的に取り組むことを目的としています。




X-Chemの最高経営責任者(CEO)であるリック・ワグナー博士は、次のように述べています。「アステラスという優れたパートナーと長期の関係を築くことができるのは当社にとって大きな喜びです。この契約は高度に連携的な活動として構成されており、アステラスの将来のポートフォリオに新規化学成分をもたらす有力な源泉になる可能性とともに、ヒト疾患の治療に有意義な影響を与える可能性も持っています。」



この複数年にわたる契約の条件に従い、X-Chemは1600万ドルの前払い金を受け取ることになります。X-Chemは研究資金に加え、創薬連携の前進にともなってライセンス料およびオプション料を受け取る権利を持ちます。またアステラスはこの連携を通じて発見された化合物につきライセンスのオプションを持ち、X-Chemはライセンスされた化合物につき、前臨床、開発、商業化の各目標に対するマイルストーン支払いを受け取る権利を得ます。今後の製品販売に基づくロイヤルティーに加え、マイルストーン支払いは、目標ごとに1億ドル以上に達することが可能です。



X-Chemの営業開発担当エグゼクティブであるO. Prem
Das博士は、次のように述べています。「この連携はX-Chemにとって、その対象範囲と持続期間という点で、変革をもたらす取引です。困難を伴う新規標的に対し、新規のリード構造を創出する上で、アステラスのニーズを満たすようにカスタマイズを行います。取引は研究の範囲を拡大するための仕組みを内包し、DEXTMを使用した創薬プロセス通じてアステラスの科学者の関与・投入を高められるようにしています。」



DNAエンコード化X-Chem(DEX™)ライブラリー/プラットフォームについて



X-ChemはDEX™ライブラリーの規模と多様性のおかげで、従来のスクリーニング手法を使用して過去に失敗したものを含む広範な標的を対象に、かつてない成功率で、新規の強力な選択的リード化合物のシリーズを多数発見することができます。ライブラリーのデザイン、スクリーニング手法、バイオインフォマティクスにおける多くの専有的イノベーションが、DEXTMプラットフォームのひときわ優れた性能の基礎となっています。特にライブラリーの構築に対するX-Chemのアプローチにより、追加的な化学反応をDNAエンコード化ライブラリーの合成で利用できます。これらの成果は全体として、以前にも増して多様なレパートリーの低分子をもたらし、フラグメント分子、低分子量複素環式化合物、大環状構造を含む広範なカテゴリーをカバーします。この多様なライブラリーは、活性分子を発見する高い能力との組み合わせで、強固なプロセスをもたらしました。このプロセスは、標的化が困難または不可能というカテゴリーに分類された標的に対し高い成功率を収めています。



DNAエンコーディングについて



X-Chemの創薬エンジンが基礎を置くライブラリーは現在、化合物数が1200億種を超えて拡大中ですが、低分子の反復型コンビナトリアル合成によって生成され、これら低分子は合成の履歴を記録したDNAタグにつながれます。ライブラリーに含まれる低分子にはすべて、独自のDNAバーコードが付けられています。目的の標的への親和性に基づく結合を使用し、混合物としてライブラリーのスクリーニングが行われます。ライブラリーの中で、標的に結合するまれな特定分子を「釣り上げ」、残りの分子は洗い流すことができます。次いでDNAシーケンシング法を使用して、標的に結合して高密化される分子を発見します。ライブラリーが備えている多様性は、標的に結合する関連分子のファミリーないしクラスターを複数作り出し、創発的な構造活性相関の基盤を形成します。構造活性相関は一般的に、医薬品化学者が特定の分子から医薬品へと化学的に繰り返し洗練させる際の導きとして使用されます。次いでDNAシーケンシング情報でエンコードされた合成の履歴に基づき、DNAのタグ付けなしに分子を作り出し、従来のアッセイで活性の試験を行います。



X-Chemについて



X-Chem,
Inc.はマサチューセッツ州ウォルサムに拠点を置く非上場バイオテクノロジー企業です。当社の使命は、保有する強力な生産エンジンを、高価値の治療標的に対する低分子化合物の発見に適用することです。X-Chemはロシュ、アストラゼネカ、バイエル、ファイザー、アレクシオン、MDアンダーソンがんセンター、サノフィ、ヤンセン、その他幾つかの一流の製薬会社、バイオテクノロジー組織、学術センターと提携関係を築いています。X-Chemの詳細情報についてはhttp://www.x-chemrx.com/をご覧ください。



アステラス製薬について



東京に拠点を置くアステラス製薬は、革新的で信頼できる医薬品の提供を通じて世界中の人々の健康を向上させることに献身する企業です。当社は優先的な治療領域として泌尿器科、オンコロジー、免疫、腎臓科、神経科に集中すると同時に、新しい技術や手段を活用して新たな治療領域や創薬研究を前進させています。また当社は医療/保健事業における内部の能力と外部の専門力を組み合わせることで、新しい価値を創出しています。アステラスは医療変革の最前線に身を置き、革新的な科学成果を患者にとっての価値に転換しています。詳細情報については当社ウェブサイト(www.astellas.com/en)をご覧ください。



本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。


Contacts


X-Chem, Inc.
Edward E. Koval, 781-419-6900
Senior Vice
President, Corporate Development
or
Media:
Suda
Communications LLC
Maureen L. Suda, 585-387-9248

New Original Programming from WAKUWAKU JAPAN "WAKUWAKU be P… 2017年03月21日 13時00分

TOKYO--(BUSINESS WIRE)--WAKUWAKU JAPAN CORPORATION (Headquarters: Minato Ward, Tokyo; President
& CEO: Masafumi Kawanishi) is set to begin broadcasting of a new,
original program, WAKUWAKU be Ponkickies, from Saturday, March
25, 2017, onward in Indonesia, Myanmar, Singapore, Taiwan, Sri Lanka,
and Mongolia.




WAKUWAKU be Ponkickies will be a specially-created version of the
educational variety program for young children and infants currently
broadcast on BS Fuji TV, be Ponkickies. That program, which began on
Fuji Television in 1973 as Hirake! Ponkikki (Open Wide! It’s Ponkicky),
has continued to be a children’s favorite throughout the more than forty
years of iterations it has seen. WAKUWAKU JAPAN has undertaken, in
collaboration with FUJI TELEVISION KIDS ENTERTAINMENT, Inc., and
YURAYURA KICK, Inc., to edit be Ponkickies primarily into shorter
content, making it easier for children outside of Japan to understand.
There has also been an effort to create a segment within the program
that features WAKUWAKU JAPAN characters, named “Kana-s”, who can blend
seamlessly within the be Ponkickies format. These characters, formed
from the WAA and KUU Japanese katakana characters, will introduce
viewers to the katakana writing system with fun rhythms and music. They
will bring a new, fun, learning experience to children across the globe,
together with many adorable characters and animations.



Japan’s children’s educational programming is well-received abroad for
the structure and quality imagery employed within the programming. There
have been a lot of audience needs for educational programming for
children that parents not only feel safe when the children watch, but
that also help form an educational foundation as they grow. This new
programming is designed to meet those needs and will additionally serve
to share a variety of Japanese experiences, using superlative
educational and entertainment content, and incorporating
program-external business, including merchandising that takes advantage
of the characters that appear within the show.






















































































Broadcast Overview




• Program: WAKUWAKU be Ponkickies




• Airing in: Indonesia, Myanmar, Singapore, Taiwan, Sri Lanka, and
Mongolia




• Broadcast Times:



Country

 

Start Date for Broadcasting

 

Time

 


Language*



Indonesia


Saturday, March 25, 2017


Every Saturday, 7:00 to 7:30AM


Indonesian

Myanmar


Saturday, March 25, 2017


Every Saturday, 6:30 to 7:00AM


English

Singapore


Saturday, March 25, 2017


Every Saturday, 7:00 to 7:30AM


English

Taiwan



Sunday, March 26, 2017




Every Sunday, 7:30 to 8:00AM


Chinese

Sri Lanka


Saturday, March 25, 2017


Every Saturday, 5:30 to 6:00AM


English

Mongolia

 

Saturday, March 25, 2017

 

Every Saturday, 8:00 to 8:30AM

 

English


* To be dubbed for each language.



 


WAKUWAKU JAPAN CORPORATION Profile
Company Name: WAKUWAKU
JAPAN CORPORATION
Address: 7F Akasaka Enokizaka Building, 1-7-1
Akasaka, Minato-ku, Tokyo 107-0052
Established: May 1, 2015
Capital:
5.5 billion yen
President & CEO: Masafumi Kawanishi
Major
shareholder: SKY Perfect JSAT 60%, Cool Japan Fund Inc. 40%
Official
site: http://www.wakuwakujapan.tv/
Countries
and regions currently broadcasting:
Indonesia, Myanmar, Singapore,
Thailand, Taiwan, Sri Lanka, Vietnam and Mongolia


Contacts


Inquiry:
WAKUWAKU JAPAN CORPORATION
Tomoko Karasawa and Minyi
Ren
Email: info@wakuwakujapan.com
Tel:
+81 3 5571 6880



Share Happiness! Pocky Announces the Number of Happiness Sh… 2017年03月21日 13時00分

OSAKA, Japan--(BUSINESS WIRE)--In commemoration of Pocky day on November 11, Japanese food manufacturer
Ezaki Glico Co., Ltd. (Osaka, Japan) launched the “Pocky day SMILE
COUNTER campaign”
on last November, calling participants to
collect smiles. The campaign was activated in Japan, China, Taiwan,
Indonesia, and Malaysia where Pocky, one of the most popular Japanese
chocolate biscuits celebrating its 50th anniversary, is
widely enjoyed.
Today, Glico has announced the number of total
smiles collected through the campaign. SMILE COUNTER has collected 447651
smiles!

With the brand message of “Share happiness!” Pocky
encourages people to share happiness and yumminess with their family and
friends. Pocky day 2016 was Pocky’s first attempt to bring that brand
message outside of Japan. “Pocky day SMILE COUNTER” was created not just
to collect smiles but to get the world to understand how simple and fun
it is to share happiness!








The official website for “Pocky day SMILE COUNTER campaign” had a
“SMILE COUNTER” which counts the total number of smile photos in real
time on the participant’s Facebook (in China Weibo) collected over the
course of the campaign.
There were events to enjoy SMILE COUNTER
and to celebrate the first global Pocky day in several countries which
attracted many people.



Pocky’s first step to introduce Pocky day to the world was successful.
The brand will continue its effort to engage with the people around the
world with the universal concept of Share happiness!



November 11th is Pocky and Pretz day in Japan
Ezaki
Glico celebrated November 11 as “Pocky and Pretz day in Japan which has
been certified by the Japan Anniversary Association. Pocky is a
signature stick-shaped chocolate biscuit. Because its shape resembles
the number “1,” Pocky and Pretz day started on November 11, Heisei 11
(Japanese era name 1999), on an auspicious day when the number “1”
aligned 6 times. The campaign is held every year during the autumn
outing season to express gratitude to our customers.



About Pocky
Pocky - also known
as Mikado in Europe – was developed when the idea was suggested of
coating the already popular Pretz pretzel-like stick snack treat with
chocolate. At first, the sticks were manually dipped leaving an uncoated
portion at one end so that they could be held without having to worry
about the fingertips becoming soiled. As demand increased, however,
manual processing could no longer keep up. As a result, the innovation
and creativity of engineers was fired up to develop a "Glico-Original"
manufacturing plant.



Pocky in the World - 500 Million boxes in 30 Countries!
Glico
is expanding its business rapidly in the world, especially in the ASEAN
regions. Pocky is the forerunner and the core of this growth. With 500
million boxes sold in about 30 countries, Pocky is now becoming a brand
loved by the world.



About Ezaki Glico
Ever since the launch in 1922 of the
nutritious, fortified Glico caramel in its distinctive red box, the
business activities of Ezaki Glico Co., Ltd. adhered to the corporate
philosophy of "Enhancing Public Health Through Food." Upon the 70th
anniversary of the Glico Group in 1992, this same spirit and dedication
was incorporated into the revised corporate philosophy of "A Wholesome
Life in the Best of Taste."
Glico caramel – the company's
first product – incorporates the innovative creativeness of Mr. Ri-ichi
Ezaki, the company's founder. Ever since the beginning, the entire staff
has likewise been heartily dedicated to further enhancing people's
health and quality of life. This has led to the expansion of business
lines beyond confectionery to include ice cream products, processed
foods, desserts, milk products, baby formula, food ingredients, and raw
materials for cosmetic and health products.




Contacts


Press Contact:
Ezaki Glico
Public
Relations
koho-hodo@glico.co.jp



Toshiba to Supply Taiwan with World's Largest Class S-Band … 2017年03月21日 11時00分



  • Order from GECI GROUP for Taiwan Central Weather Bureau


  • World’s largest class antenna delivers wide area observation with
    range of 400 km



  • Microwave transistor realizes high level observation capabilities
    of Typhoon Alley



TOKYO--(BUSINESS WIRE)--Toshiba Corporation (TOKYO:6502) today announced that it will contribute
to better understanding of weather conditions in Taiwan by providing the
Taiwan Central Weather Bureau with an S-band weather radar system with
an antenna in the world’s largest class, for installation in Chigu
district, Tainan city. The system, to be delivered by Toshiba with High
Bound Co., Ltd, a Taiwanese engineering company, under an order received
from GECI GROUP (GECI), Spanish system integration and high-technology
company, will have a range of approx. 400km, and will support high
resolution imaging of precipitation and wind velocity, essential for
accurate, pinpoint weather forecasting. Toshiba, High Bound and GECI
will deliver the system in 2019.




The western Pacific, long known as Typhoon Alley, is home to some of the
world’s strongest tropical cyclones, including the strongest ever
recorded, Typhoon Tip. Taiwan is regularly hit by typhoons, such as
Nepartak, which made landfall in July 2016, causing extensive damage and
claiming three lives. As a mountainous island where torrential rains can
quickly result in landslides and flooding, Taiwan must be constantly
ready to deal with the risk of such disasters, and deployment of
Toshiba’s S-band radar will make a major contribution to the island’s
state of readiness.



The radar system adopts dual polarization and Toshiba’s state-of-the-art
microwave transistors to deliver wide area observation, and achieves
high level observation capabilities and accuracy. The system also
integrates several redundant microwave transistors to maintain operation
if some cease operation. Toshiba received the order following GECI’s
technical review and price evaluating.



Masaki Haruyama, Vice President of the Defense & Electronic Systems Div.
in Toshiba’s Infrastructure Systems & Solutions Company said, “We are
very pleased to have received our first order for a weather radar system
for Taiwan. We are confident the system will contribute to advancing
weather observation capabilities and the provision of timely, reliable
forecasts.”



In addition to S-band weather radars for wide-area observations, Toshiba
also develops and delivers X-band dual polarization transportable
Doppler weather radar systems for more localized monitoring. The company
is focused on expanding sales of these systems in countries where severe
weather is a source of concern and disaster prevention systems are
needed, including India and Southeast Asia region.



About Toshiba
Toshiba
Corporation, a Fortune Global 500 company, channels world-class
capabilities in advanced electronic and electrical product and systems
into three focus business fields: Energy that sustains everyday
life, that is cleaner and safer; Infrastructure that sustains
quality of life; and Storage that sustains the advanced
information society. Guided by the principles of The Basic Commitment of
the Toshiba Group, “Committed to People, Committed to the Future”,
Toshiba promotes global operations and is contributing to the
realization of a world where generations to come can live better lives.



Founded in Tokyo in 1875, today’s Toshiba is at the heart of a global
network of 551 consolidated companies employing 188,000 people
worldwide, with annual sales surpassing 5.6 trillion yen (US$50
billion). (As of March 31, 2016.)
To find out more about Toshiba,
visit www.toshiba.co.jp/index.htm




Contacts


Press Contact:
Toshiba Corporation
Hirokazu Tsukimoto
and Seiji Ishibashi, +81-3-3457-2100
PR & IR Division
media.relations@toshiba.co.jp

Top 5 Vendors in the Global Prepreg Market From 2017-2021: … 2017年03月21日 03時03分

LONDON--(BUSINESS WIRE)--$CE #Fiber--Technavio
has announced the top five leading vendors in their recent global
prepreg market
report from 2017-2021. This research
report also lists 13 other prominent vendors that are expected to impact
the market during the forecast period.








The research study by Technavio on the global
prepreg market
for 2017-2021 provides a detailed industry
analysis based on type of reinforcement (prepreg carbon fiber,
glass fiber prepreg, and aramid fiber prepreg), application (aerospace
and defense, wind energy, and automotive), and geography (North America,
APAC, and ROW).



Prepregs are fiber reinforcement pre-impregnated with a resin.
The resins are often either thermoset or thermoplastic. Lightweight
prepreg
materials are in great demand from the
automotive
industry
to increase fuel efficiency and incorporation
of high-speed manufacturing technologies. This demand from the
automotive industry is one of the key drivers responsible for the growth
of the market
,” says Mahitha Mallishetty, a lead analyst at
Technavio for textile,
fiber, and composites
research.



Competitive vendor landscape



The market is dominated by global vendors such as Celanese, Cytec
Solvay Group
, Mitsubishi Rayon (MRC), Teijin, and Toray.
The global prepreg market is highly competitive in nature, with vendors
competing on the basis of product performance and quality, price,
product availability, security of supply, and customer service.
Competitors are aggressive while offering alternate products that are
based on novel technologies and processes, and price their products
based on performance alone. Also, market vendors who incorporate
environmental management programs that include eco-friendly and
cost-effective manufacturing practices gain a strategic edge over their
competitors.



Request a sample report: http://www.technavio.com/request-a-sample?report=57095



Technavio’s sample reports are free of charge and contain multiple
sections of the report including the market size and forecast, drivers,
challenges, trends, and more.



About the top five prepreg market vendors



Celanese



Celanese operates through four major segments: acetyl intermediates,
advanced engineered materials, consumer specialties, and industrial
specialties. The company also specializes in manufacturing
ethylene-vinyl acetate polymers, intermediate chemistry, cellulose
derivatives, emulsion polymers, food ingredients, and engineered
materials.



Cytec Solvay Group



Cytec Solvay Group is a chemical manufacturing company, which
specializes in the production of specialty polymers, polyamides and
intermediates, essential chemicals, silica and rare earth systems,
consumer chemicals, vinyl, and acetate tow. It also provides barium,
strontium, calcium chloride, caustic soda, and specialty polymers.



Mitsubishi Rayon



Mitsubishi Rayon is engaged in the production of chemical products such
as resins, fibers, carbon fibers, composite materials, and membranes.
The company produces thermoset epoxy resin-impregnated woven carbon
fabric, high-performance structural film adhesives, composite prepregs
(carbon, aramid, and glass), and TowPregs for the marine, aerospace,
aviation, military, medical, industrial, and sports sectors.



Teijin



Teijin offers solutions related to the sustainable transportation,
safety and protection, information and electronics, environment and
energy, and healthcare sectors. The company’s key focus areas are
high-performance fibers such as aramid fibers, carbon fibers,
composites, films, resins, and plastics.



Toray



Toray engages in the processing, manufacturing, and marketing of
plastics and chemicals, fibers and textiles, carbon fiber composite
materials, and IT-related products. The company also offers products
related to businesses such as environment, engineering, and life
sciences.



Browse Related Reports:




Become a Technavio
Insights member
and access all three of these reports for a
fraction of their original cost. As a Technavio Insights member, you
will have immediate access to new reports as they’re published in
addition to all 6,000+ existing reports covering segments like
chemical
engineering equipment
, glass
and ceramics
, and industrial
gases
. This subscription nets you thousands in savings, while
staying connected to Technavio’s constant transforming research library,
helping you make informed business decisions more efficiently.



About Technavio



Technavio
is leading global technology research and advisory company. The company
develops over 2000 pieces of research every year, covering more than 500
technologies across 80 countries. Technavio has about 300 analysts
globally who specialize in customized consulting and business research
assignments across the latest leading edge technologies.



Technavio analysts employ primary as well as secondary research
techniques to ascertain the size and vendor landscape in a range of
markets. Analysts obtain information using a combination of bottom-up
and top-down approaches, besides using in-house market modeling tools
and proprietary databases. They corroborate this data with the data
obtained from various market participants and stakeholders across the
value chain, including vendors, service providers, distributors,
resellers, and end-users.



If you are interested in more information, please contact our media team
at media@technavio.com.




Contacts


Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Keio Plaza Hotel Tokyo Hosts Exhibition of Spectacular Ikeb… 2017年03月20日 23時00分


Decorating Lobby with Beautiful “Sakura” Cherry Blossoms


TOKYO--(BUSINESS WIRE)--#art--Keio
Plaza Hotel Tokyo
, one of Japan’s most prestigious international
hotels located in Shinjuku, Tokyo, will host a special exhibition of “Ikebana”
flower arrangement
created by the renowned artist Hiroki
Maeno
from April 1 to 16, 2017. A large 2.7 by 5 meter flower
arrangement lavishly adorned with some 200 beautiful “sakura” cherry
blossom branches, which are one of the most symbolically important
representatives of the Japanese aesthetic beauty during the spring, will
be displayed in the third floor main lobby area for hotel guests to
enjoy free of charge.








The artist Hiroki Maeno will also provide two Ikebana flower arrangement
workshops held on April 6 from 4:00p.m. and 6:30p.m. in front of his
beautiful arrangement. Guests will be able to view these workshops as
they will be held in the lobby area.



About 75% of the guests staying at the Keio Plaza Hotel are overseas
visitors from over 100 different countries. Therefore, our hotel has
hosted exhibitions of Maeno’s Ikebana flower arrangements four times a
year to show our guests the Japanese traditional sense of Japanese
aesthetic beauty during each of the four seasons. These arrangements
also demonstrate the artist Maeno’s abilities as a space producer.
Furthermore, the upcoming exhibition will provide guests with a rare
opportunity to enjoy the “sakura” cherry blossoms, which only remain in
bloom for one to two weeks and are expected to have already fallen off
the trees in the Tokyo region by the time that this exhibition is held.



[Ikebana Flower Arrangement Artist Hiroki Maeno]
Hiroki
Maeno
produces many different styles which pleasantly surprise all
those who view them. He has been given a guild name “Flower Artisan
Maeno” in recognition of his extreme talents and abilities, as well as
“Flower Arrangement Architect” because of the beauty and grand scale of
his flower arrangements. He has been asked to create flower arrangements
for the APEC Energy Meeting held in Kyoto, the 1300 Year Anniversary of
the Jinguji Temple, and numerous other events including television
programs and plays.



Full
Version of Press Release




Contacts


Keio Plaza Hotel Tokyo
Sunaho Nakatani, +81-3-5322-8010
Public
Relations Manager
s-nakatani@keioplaza.co.jp



ServiceMax Appoints Takahiro Kouke as General Manager of Ja… 2017年03月20日 22時00分

PLEASANTON, Calif.--(BUSINESS WIRE)--#fieldservice--ServiceMax,
a GE
Digital
company and the leader in cloud-based field service
management solutions, today announced it has appointed Takahiro Kouke as
General Manager of Japan, where he will focus on expanding the company’s
customer base in the burgeoning market.



Kouke joins ServiceMax after spending more than 25 years scaling
operations and building sales and marketing teams across a variety of
roles and companies in Japan. Most recently, Kouke launched Radware’s
cloud security business in Japan, and managed all aspects of operations
in the region. Prior to that, he served as country manager for Opower
(acquired by Oracle) and Novel (acquired by Microfocus), and vice
president for Coverity (acquired by Synopsys) and Cisco (via Tanberg
acquisition).



ServiceMax has seen an expanding opportunity in Japan since it launched
its local effort in 2015. Of note are partnerships ServiceMax has
announced with Hitachi,
Pro-SPIRE
and ISID,
and the successful deployment at customer Screen
GP
. According to leading market research firm ITR,
as of 2015 the field service management market in Japan comprises an
approximate ¥3.7 billion opportunity, and is forecast to grow to ¥5.8
billion by 2019.



And as our recent
survey
indicated, our customers are deriving dramatic business
benefits from modernizing field service, on average seeing revenue
increase by 13 percent and costs decrease by 8 percent. As such,
ServiceMax expects more companies to begin transforming service
operations.



“Field service management technology can have a profound impact on
industrial companies looking for growth in an otherwise stagnant space,”
said Kouke. “I am looking forward to helping companies tap into their
service organizations to improve profitability, customer satisfaction
and productivity through ServiceMax’s end-to-end field service platform.”



“Takahiro brings a wealth of experience to our growing Japan operations,
where we see a huge opportunity to deploy ServiceMax more broadly,” said
Spencer Earp, Executive Vice President, EMEA & APAC, ServiceMax. “As our
customers continue to showcase the dramatic benefits they’re seeing
we’re excited to have Takahiro leading the charge in this region.”



About ServiceMax



ServiceMax, a GE Digital company, leads the massive global industry of
field service management software – an estimated $25 billion market
worldwide. The company continues to reimagine and create solutions for
the 20 million people globally who install, maintain, and repair
machines across dozens of industries as the leading provider of complete
end-to-end mobile and cloud-based technology for the sector. ServiceMax
goes to every length – from joining technicians on service calls to
publishing the industry's leading online publication – to help customers
discover untapped innovation, unleash new revenue streams, drive
efficiency, and most importantly delight their end-customer. To learn
more, please visit www.servicemax.com.




Contacts


ServiceMax
Elliott Burr, 925-621-1434
Elliott.Burr@servicemax.com

Novocure Receives MHLW Approval for Second Generation Optun… 2017年03月20日 20時00分


Second generation Optune is now approved in all active Novocure
markets




Optune is the first MHLW-approved therapy in more than a decade to
demonstrate statistically and clinically significant extension of
survival in newly diagnosed GBM patients


ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) today announced that the Japanese Ministry of
Health, Labour and Welfare (MHLW) has approved second generation Optune.
Second generation Optune features a Tumor Treating Fields (TTFields)
generator that is less than half the weight and half the size of the
first generation generator, weighing less than 1.3 kilograms (2.7
pounds). The smaller, lighter TTFields delivery system is now available
to glioblastoma (GBM) patients in all of Novocure’s active markets.



“The MHLW’s approval of second generation Optune represents another
important milestone for Novocure in Japan as we prepare for a broad
commercial launch pending reimbursement approval,” said Shungo Matori,
Novocure’s General Manager, Japan and Representative Director of
Novocure K.K. “We are dedicated to making Optune available to GBM
patients who can benefit from our therapy. This approval enables us to
provide Japanese patients with the latest TTFields technology, designed
to be make it even easier for patients to incorporate treatment with
Optune into their lives.”



Novocure established commercial operations in Japan in March 2015 after
the MLHW approved Optune for the treatment of recurrent GBM. In December
2016, the MLHW approved Optune for the treatment of newly diagnosed GBM
and Novocure is currently preparing to submit an application for public
reimbursement of Optune. Approximately 1,500 people are diagnosed with
GBM or tumors that typically progress to GBM in Japan each year.



The MHLW’s approval of Optune for the treatment of newly diagnosed GBM
was supported by Novocure’s phase 3 pivotal EF-14 trial results, which
showed significant extension of both progression free and overall
survival in newly diagnosed GBM patients receiving Optune with
temozolomide compared to temozolomide alone. Optune is the first
MHLW-approved therapy in more than a decade to demonstrate statistically
and clinically significant extension of survival in newly diagnosed GBM.



About Novocure



Novocure is an oncology company developing a profoundly different cancer
treatment centered on a proprietary therapy called TTFields, the use of
electric fields tuned to specific frequencies to disrupt solid tumor
cancer cell division. Novocure’s commercialized product, Optune, is
approved for the treatment of adult patients with glioblastoma. Novocure
has built a commercial organization and launched Optune for the
treatment of GBM in the United States, Germany, Switzerland and Japan,
referred to as Novocure’s currently active markets. Novocure has ongoing
or completed clinical trials investigating TTFields in brain metastases,
non-small cell lung cancer, pancreatic cancer, ovarian cancer and
mesothelioma.



Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the
company has offices in Germany, Switzerland and Japan, and a research
center in Israel. For additional information about the company, please
visit www.novocure.com
or follow us at www.twitter.com/novocure.



Approved Indications



In Japan, Optune (NovoTTF-100A) is approved in the treatment of adult
patients with supra-tentorial glioblastoma (GBM) and is used following
maximal safe surgical resection and radiation therapy.



In the United States, Optune is intended as a treatment for adult
patients (22 years of age or older) with histologically-confirmed
glioblastoma multiforme (GBM).



In the United States, Optune with temozolomide is indicated for the
treatment of adult patients with newly diagnosed, supratentorial
glioblastoma following maximal debulking surgery and completion of
radiation therapy together with concomitant standard of care
chemotherapy.



In the United States, for the treatment of recurrent GBM, Optune is
indicated following histologically-or radiologically-confirmed
recurrence in the supratentorial region of the brain after receiving
chemotherapy. The device is intended to be used as a monotherapy, and is
intended as an alternative to standard medical therapy for GBM after
surgical and radiation options have been exhausted.



Important Safety Information



Contraindications: Do not use Optune if you have an active
implanted medical device, a skull defect (such as, missing bone with no
replacement), or bullet fragments. Use of Optune together with implanted
electronic devices has not been tested and may theoretically lead to
malfunctioning of the implanted device. Use of Optune together with
skull defects or bullet fragments has not been tested and may possibly
lead to tissue damage or render Optune ineffective.



Do not use Optune if you are known to be sensitive to conductive
hydrogels. In this case, skin contact with the gel used with Optune may
commonly cause increased redness and itching, and rarely may even lead
to severe allergic reactions such as shock and respiratory failure.



Warnings and Precautions: Use Optune only after receiving
training from qualified personnel, such as your doctor, a nurse, or
other medical personnel who have completed a training course given by
Novocure (the device manufacturer).



Do not use Optune if you are pregnant, you think you might be pregnant
or are trying to get pregnant. It is not known if Optune is safe or
effective in these populations.



The most common (≥10%) adverse events involving Optune in combination
with temozolomide were low blood platelet count, nausea, constipation,
vomiting, fatigue, scalp irritation from device use, headache,
convulsions, and depression.



The most common (≥10%) adverse events seen when using Optune alone were
scalp irritation from device use and headache.



The following adverse reactions were considered related to Optune when
using the device alone: scalp irritation from device use, headache,
malaise, muscle twitching, fall and skin ulcer.



All servicing procedures must be performed by qualified and trained
personnel.



Do not use any parts that do not come with the Optune Treatment Kit, or
that were not sent to you by the device manufacturer or given to you by
your doctor.



Do not wet the device or transducer arrays.



If you have an underlying serious skin condition on the scalp, discuss
with your doctor whether this may prevent or temporarily interfere with
Optune treatment.



Please see http://www.optune.com/safety
to see the Optune Instructions For Use (IFU) for complete information
regarding the device’s indications, contraindications, warnings, and
precautions.



Forward-Looking Statements



In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, development of potential
products, interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market prospects
for its products, and other statements regarding matters that are not
historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as “anticipate,”
“estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other
words and terms of similar meaning. Novocure’s performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 23, 2017, with the U.S. Securities
and Exchange Commission. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.




Contacts


Media and Investors:
Novocure
Ashley Cordova,
212-767-7558
acordova@novocure.com



企業をしらべれば人生が変わる! -就活やビジネスを成功に導くユーレット活用術-
スポンサードリンク